

US EPA ARCHIVE DOCUMENT

----- X  
:  
FIFRA SCIENTIFIC ADVISORY :  
:  
PANEL (SAP) OPEN MEETING :  
:  
-----X

METHODS USED TO CONDUCT A PRELIMINARY CUMULATIVE  
RISK ASSESSMENT FOR ORGANOPHOSPHATE PESTICIDES

February 7, 2002

[8:30 a.m.]

SHERATON CRYSTAL CITY HOTEL  
1800 Jefferson Davis Highway  
Arlington, Virginia 22202

1

**PARTICIPANTS**

2

**FIFRA SAP Session Chair**

3

Stephen Roberts, Ph.D.

4

5

**Designated Federal Official**

6

Ms. Olga Odiott

7

8

**FIFRA Scientific Advisory Panel Members**

9

Dr. Herbert Needleman, M.D.

10

Christopher J. Portier, Ph.D.

11

Stephen M. Roberts, Ph.D.

12

Mary Anna Thrall, D.V.M

13

14

**FQPA Science Review Board Members**

15

John Adgate, Ph.D.

16

William Brimijoin, Ph.D.

17

Richard Bull, Ph.D.

18

Rory Conolly, Sc.D.

19

Patrick Durkin, Ph.D.

20

Natalie Freeman, Ph.D.

21

Jean Harry, Ph.D.

3

- 1 Dale Hattis, Ph.D.
- 2 Steven Herringa, Ph.D.
- 3 Ernest McConnell, D. V.M.
- 4 Peter MacDonald, D. Phil.
- 5 Nu-May Ruby Reed, Ph.D.
- 6 Lorenz Rhomberg, Ph.D.
- 7 Lauren Zeise, Ph.D.

1 DR. ROBERTS: Good morning and welcome to the February 7  
2 meeting of the FIFRA Scientific Advisory Panel. This is the third day  
3 in a consultation between the Panel and the Agency topic of  
4 cumulative risk assessment of organophosphate pesticides.

5 My name is Steve Roberts. It's my pleasure to serve as chair  
6 today. Before we the Panel for today's session, I'd to introduce our  
7 designated federal official for today's session, Ms. Olga Odiott. Good  
8 morning, Olga.

9 MS. ODIOTT: Good morning, Dr. Roberts. I want to welcome  
10 everybody to this important meeting of the of the FIFRA Scientific  
11 Advisory Panel. For the benefit of those who are you joining us today  
12 for the first time, this meeting is being conducted under the provisions  
13 of the Federal Advisory Committee Act. And all background materials  
14 and all documents related to these meetings are available from the  
15 Office of Pesticides Programs docket. And many of the materials are  
16 also available from the EPA web site. Your agenda lists the contact  
17 information for both places.

18 I would like to thank the Panel members for their commitment,  
19 for their contributions, and for their willingness to be with us during  
20 this process and to provide to the Agency the much appreciated  
21 feedback on these issues. And we're looking forward to very good

5

1 discussions today. Thank, Dr. Roberts.

2 DR. ROBERTS: We have a new Panel member with us joining  
3 us today and there's possibility that there are some folks in the  
4 audience who have not been with us previously. So I think it would be  
5 useful for the Panel to introduce themselves. So let me ask the Panel,  
6 beginning on my far right, and then proceeding around the table  
7 clockwise, and for each member to state their affiliation, and the  
8 expertise they bring to today's discussion.

9 DR. BULL: I'm Dick Bull from Washington State University.  
10 My expertise is in toxicology.

11 DR. DURKIN: I'm Pat Durkin. I'm with Syracuse  
12 Environmental Research Associates. I do pesticide risk assessments  
13 for the USDA, and I've been involved with the EPA in risk assessment  
14 issues.

15 DR. HARRY: Jean Harry. National Institute of Environmental  
16 Health Sciences in North Carolina. My background expertise is in  
17 neurotoxicity.

18 DR. CONOLLY: Rory Conolly CIIT Centers for Health  
19 Research in Research Triangle Park, North Carolina. I'm toxicologist  
20 with a strong interest in mechanisms of toxicity that underlie the shape  
21 of the dose response curve and in the development of computer models

6

1 of those mechanisms.

2 DR. RHOMBERG: I'm Laurez Rhomberg from Gradient  
3 Corporation, also, adjunct professor at the Harvard School of Public  
4 Health. And I'm interested in several aspects of quantitative modeling  
5 and risk assessment.

6 DR. MCCONNELL: I'm Gene McConnell. I'm veterinary  
7 pathologist and toxicologist from Raleigh, North Carolina, Toxpath,  
8 Incorporated. My area of expertise, as I said, was in comparative  
9 pathology, toxicology, particularly as they relate to bioassays done in  
10 experimental animals.

11 DR. KENDALL: I'm Ron Kendall. I'm a member of the Science  
12 Advisory Panel. I'm from Texas Tech University. I'm professor and  
13 chairman of the Department of the Environmental Toxicology. And I  
14 also direct the Institute of Environmental and Human Health at the  
15 university. Area of interest is toxicology and risk assessment.

16 DR. HATTIS: Hi. I'm Dale Hattis from Clark University. I do  
17 a fair amount of pharmacokinetic analysis and I focus on issues of  
18 variability and uncertainty in risk analyses in general.

19 DR. ADGATE: I'm John Adgate from the University of  
20 Minnesota School of Public Health. And my area of research interest  
21 and expertise is in exposure analysis and risk assessment methodology.

7

1 DR. REED: Mu-May Ruby Reed from California Environmental  
2 Protection Agency, Department of Pesticide Regulation. I do  
3 pesticide risk assessment.

4 DR. FREEMAN: Natalie Freeman, Robert Wood Johnson  
5 Medical School and the Environmental and Occupational Health  
6 Sciences Institute in Piscataway, New Jersey. I look at residential and  
7 children's exposure.

8 DR. MACDONALD: Peter MacDonald from Mathematics and  
9 Statistics at McMaster University in Canada. I have a general  
10 expertise in applied statistics and model fitting.

11 DR. HEERINGA: Steve Heeringa from the Institute for Social  
12 Research at the University of Michigan. I'm a biostatistician with  
13 specialization in epidemiology and population-based studies.

14 DR. ROBERTS: And I'm Steve Robert. I'm a professor at the  
15 University of Florida in the Colleges of Medicine and Veterinary  
16 Medicine. I'm also director of the Center for Environmental and  
17 Human Toxicology. My research interests are in mechanisms of  
18 toxicity, particularly pertaining to the liver and immune system and  
19 toxicokinetics. And I have a working interest in risk assessment.

20 I'm delighted that we have with us for our session again the  
21 Director of Office of Pesticide Programs, Ms. Marsha Mulkey.

8

1           Good morning, Ms. Mulkey. Welcome. Did you have comments  
2 or would you like to address the Panel before we get started today?

3           MS. MULKEY: I will just a moment in the midst of this  
4 marathon -- I feel like I should offer some water bottles to the Panel --  
5 to thank you just in case the latter part of the day doesn't offer that  
6 opportunity for this extraordinary session. And, of course, it's a  
7 culmination of a number of important and indeed critical sessions. But  
8 this is very important to us, to our work, to our credibility, to our  
9 service to the American people.

10           And I think, as many of you have noted, it also lays a  
11 groundwork for the work of many others, us and many others, as we  
12 go forward trying to understand ways of thinking about sources of  
13 exposure that are beyond a single chemical.

14           So we are very gratified by the value that has already been  
15 added. We look forward to today and to your report and to our  
16 continuing collaboration and consultation as we go forward. Thank  
17 you.

18           DR. ROBERTS: I would like to add that your input during our  
19 discussions over the last couple of days have been very valuable to the  
20 Panel. You've been a real asset to our discussions having you here  
21 with us.

9

1 MS. MULKEY: That's very gracious. I feel it has been modest  
2 at best but thank you.

3 DR. ROBERTS: Margaret Stasikuwski of OPP, welcome this  
4 morning. Would you like to introduce the presenters and the scientists  
5 you have with us today?

6 MS. STASIKUWSKI: Yes, this morning's presentation will be  
7 made by Jeff Evans. And sitting to go my left is Dr. Randy Perfetti,  
8 also from our division, deputy director.

9 DR. ROBERTS: Dr. Perfetti, did you want to give us a recap?  
10 I think was originally on the schedule for the morning.

11 DR. PERFETTI: Only insofar as to again welcome the Panel  
12 and then give our sincere thanks for the previous two days and the  
13 sessions and the great advise you've given us. We really appreciate it.

14 Other than that, as Margaret said, Jeff Evans will be providing  
15 the presentation for the residential nonoccupational exposure part of  
16 this risk assessment. And this afternoon, Dr. Beth Evans and Dave  
17 Miller will provide the presentation for the risk characterization part  
18 of this assessment.

19 Thank you, Dr. Roberts.

20 DR. ROBERTS: Welcome, Mr. Evans. We'll be delighted to  
21 hear your presentation on the residential aspect of the cumulative risk

10

1 assessment.

2 MR. EVANS: Thank you very much. This morning I would like  
3 to go over some aspects of the residential assessment. Today we  
4 would like to talk about, briefly, how we used our calendar-based  
5 model to address the temporal aspects of the OP uses, in particular,  
6 for the residential uses.

7 I should note that this approach is similar to the approach we  
8 took to the OP Case Study presented here not that many months ago it  
9 seems. And, also, I'd like to talk a little bit about the data we used in  
10 our cumulative assessment.

11 Not all of it, but certain aspects of it that are a little difficult  
12 for us to get our thoughts around and to discuss with the Panel use of  
13 distributions of our available data and, also, additional ways to  
14 incorporate survey data that's recently become available.

15 And, also, on Tuesday, there was a presentation suggesting the  
16 types of survey data that we will be getting in the future. And it's  
17 going to be up to us to decide how to use it. And we are really  
18 looking forward to your comments with respect to those possibilities.

19 This is something very new for us, the use of survey data and,  
20 also, using distributions to accompany a wide range of exposure  
21 variables. So this is our first stab. It is a beginning. As time goes on,

11

1 we're going to have to get more sophisticated. So with that in mind, I  
2 can proceed to the next slide, please.

3 Now, just to lay out the use, I think anybody that does risk  
4 assessment, and particularly a large one like this, wrapping around all  
5 the uses is always difficult. The minute you think you have it,  
6 something else shows up. And it was also very difficult with the single  
7 chemical assessments still in progress, what was in, what was out,  
8 what were people going to support. And it's important for the Panel  
9 to know that the DDVP strip use that's presented in this assessment is  
10 no longer registered and that's going to change.

11 The pet uses for DDVP and Tetrachlorvinphos were not  
12 included in this preliminary assessment primarily because we're still, I  
13 think all of us, are really still working with the difficulty of modeling  
14 our relationship with pets, both the receptor and the source are  
15 constantly moving. And it's very difficult for us to model, I think,  
16 effectively without just having a screen that once loaded into a model  
17 would obviously swamp every other use.

18 So, also, perhaps in our conversations when we talk about the  
19 various aspects of exposure to maybe also think about what it would  
20 be like to model exposure to a pet wearing a collar or a pet that's been  
21 recently treated with a spray or a dip or some sort of top-spot

12

1 treatment.

2 We have home lawns. And the major uses are bensulide,  
3 malathion, and trichlorfon. And some of those uses are no doubt  
4 going to change as time goes on. Golf course uses. There's nothing  
5 like finding out that something isn't registered by someone in a public  
6 meeting. And that's certainly been the case for some of our golf-  
7 course uses. And we heard you. So if you would limit your comments  
8 to other aspects rather than that, we'd appreciate it.

9 Home gardens. We have in the ornamental sense, we have  
10 acephate and disulfoton. And for the vegetables and other edible  
11 crops, we still have registrations of malathion.

12 We also looked at the specific public health sprays for  
13 mosquitos, fenthion and malathion. And then also the use of naled for  
14 black flies up in areas of Minnesota.

15 I've been told that your slides have got this very simple equation  
16 backwards that we use every day. We know what we're talking about  
17 here. And the only point of the slide is to, obviously, point out the  
18 fact that we're looking at inhalation exposure, dermal exposure and  
19 oral exposure through the mouthing behavior of young children. So  
20 that is somewhat separate from than the dietary and drinking water  
21 assessments. Now.

1           For our age groups, we picked what we feel we have the best  
2 information with respect to the hand-to-mouth behavior. We have  
3 children in one-to-two years old and three to five. And those groups,  
4 the one-to-two-year-olds are 12 to 35 months. And the children three  
5 to five are 36 to 59. And, again, those are what we feel we have the  
6 best information for the hand-to-mouth behavior.

7           For the adults, we have all the other age groups. And I think  
8 that probably the big difference is the body weight surface area of  
9 children that has impact on the dermal exposure values. You know,  
10 they're shaped a little bit differently than we are. Obviously, their  
11 heads a little bit bigger or their trunks, arms may be a little shorter,  
12 things like that. And of course, as they get older, they become a little  
13 bit more like we are.

14           Again our focus in terms of having the number of files that went  
15 into the model, we focused on those children and adults. But in a  
16 sense we feel we really covered everybody.

17           Just briefly, we've conducted assessments for 12 distinct  
18 geographic regions. And we hope that we've reflected climate and  
19 pest pressure differences. In California, we just -- one region was put  
20 into two residential assessments. We may reevaluate that based on  
21 some of the comments we get from the public and regulator

14

1 community.

2 It includes, we believe, are the remaining residential OPs that  
3 have significant uses and appropriate exposure data. And, again, I just  
4 want to say that we have not, at this point, included the pet products;  
5 but we intend to by the time this is all over.

6 You've all seen this map many, many times over. And I think it  
7 really does point out the facts that there are differences where we live  
8 and the climate and the climate influences the types of insects that  
9 bother us. I think our main goal, really, was to, first of all, keep it  
10 simple and also really try and figure out why people were using  
11 pesticides. And I'll get into a little bit of that later. And, of course,  
12 you've seen this many times over.

13 Here's an example of the Eastern Uplands. This was the area we  
14 used in our pilot. Now this time you get to see some of the pesticides  
15 that we addressed there. We really mainly address malathion or  
16 trichlorfon.

17 And on golf courses, acephate, bensulide, fenaminphos,  
18 malathion, and trichlorfon. Ornamentals, those three as I mentioned  
19 before, the home garden, malathion, and the indoor uses of the DDVP.

20 Now this matrix, I think, is really important for people to think  
21 in terms of the files. Think of each of those as a file for a region.

15

1 What the slide does, also, is indicate the time in which something  
2 might not applied.

3 So for each and every one of these there is a AGX file that deals  
4 with all of the residue data, all the contact values, the pesticide  
5 application schedule, the percent of houses that are treated. All those  
6 things are boiled into those AGX files. And it is all those files that are  
7 then loaded into the program. And it, also, works with the DEEM.

8 And it's a lot of data to manage as you can possible imagine.  
9 There's a number of people that worked on this, Sheila Piper, Sherry  
10 Cenard, Jennifer Tylor, Dave Herd. There's an awful lot of work in  
11 managing these kinds of files. Seeing how the model goes, checking  
12 out your schedules, making sure things line up, there's obviously some  
13 things that we need to go back and fix. And we're in the process of  
14 doing that. But it was a lot of work to manage, and we really  
15 appreciate their efforts.

16 And so with those temporal aspects you do then see the efforts.  
17 The seasonal aspects in the middle there, the lines, that really is your  
18 garden uses, your lawn uses, public health happening in there. There's  
19 the use of the strips up there, your food, and this is your drinking  
20 water.

21 So this was really probably the strongest reason to do certainly

16

1 something that's, you know, geographically and temporal-based  
2 because you really want to be able to line up the possible uses and  
3 concurrence.

4 So with that said, our road map today will talk a little bit about  
5 the distribution selected for some of these key scenarios, obviously,  
6 lawns and golf courses, public health, and the garden. I'll also go  
7 through a little bit of the characterization and our feeling on how we  
8 kind of addressed it. And then, also, with a future view towards the  
9 consideration of survey data that's going to be coming available to us.

10 Now for the lawn use information, as I've said many times  
11 before, we rely primarily on the National Home and Garden Pesticide  
12 Use Survey. It was done a number of years ago, but it still is probably  
13 the best data we have available now that is related to the use of  
14 pesticides in homes. And we're able to determine the percent of  
15 households using a given pesticide. And there are regional distinction.

16 Treated lawns, there's also regional differences in the percent of  
17 the population that hire lawn-care services. So this would be  
18 important for chemicals that may be are no longer registered for  
19 application by residents but may be applied by the LCOs so that we can  
20 address the post-application exposure to those.

21 And, also, lawn sizes. Having an idea of how large someone's

17

1 lawn, which is a variable for assessing applicator exposure is difficult  
2 for us to determine, and it's going to continue to be a challenge for us.

3 And for that we selected a uniform distribution of 500 to 15,000  
4 square feet, a third of an acre, which was the median for homes, you  
5 know, throughout the country. But I think it's important to note that  
6 that only considers the lot size minus the footprint, and it really  
7 doesn't consider other things such as decks and, of course, the fact  
8 that there are gardens and other things that we are also assuming  
9 people are spraying pesticides on.

10 But all of this started out with the label. That still is kind of the  
11 legal document. And that's where we find our site-pest relationships.  
12 This is where we get the application rates. And some of them are more  
13 descriptive than others. Sometimes they'll just have a list of thousands  
14 of sites and thousands of pests and not all pests get on all sites. So  
15 it's really important to find out what is going on in the various  
16 regions.

17 And a very good place to go is the State Cooperative Extension  
18 Services. A lot of really great stuff on line, a lot of information about  
19 the timing, when to look for pests, when to spray, also  
20 recommendations on the number of applications, when to look, when  
21 to scout. Also, sort of the landscape as far as what they're

18

1 recommending. And obviously this ties into what people may use,  
2 what kind of information they'll get at garden centers.

3 And, of course, timing of applications is very important with  
4 respect to all the other aspects of potential exposures from other  
5 sources.

6 And I also looked at efficacy data that is also broken down into  
7 regions. Certain pests just don't occur in other areas. And that was  
8 an important consideration.

9 Now, for applicator exposure data, we have some pretty robust  
10 data from Outdoor Residential Exposure Task Force. This is  
11 addressing two major lawn application methods. Obviously, the  
12 push-type rotary spreader for granular formulations. That would be  
13 for bensulide and trichlorfon.

14 And then hose-end sprayers which are available as a ready to  
15 use where the concentrate is already mixed in and the person doesn't  
16 have to really handle the concentrate and the proportion is already  
17 calibrated.

18 And there is another one for those that still have the old fashion  
19 one where you have to add your own concentrate and make your own  
20 settings to determine how many gallons per thousand square feet of  
21 lawn area.

19

1           The data also address a range of clothing, which include  
2 short-sleeved shirts, short pants, up to long-sleeve shirts and long  
3 pants.

4           Just by way of example or just for people to understand what  
5 the unit exposure is, it's really the amount of pesticide that gets on an  
6 individual as a result of an activity and how much they actually used.  
7 And this would be used in our simple algorithm unit, exposure times  
8 how much the individual applied and divided by body weight.  
9 Sometimes other metrics such as dermal absorption are used. But we  
10 had a dermal endpoint for these scenarios, so we didn't make any  
11 adjustments.

12           Now the hose-end sprayer, we have for this go-around anyway,  
13 we used uniform distribution. Obviously, there's quite a range there.  
14 And we've also done the same thing for the granular applicators.

15           Now as far as an activity pattern, this is pretty easy to  
16 understand. And it's also easy to measure. We selected a uniform  
17 distribution that would reflect a range of clothing to be worn because  
18 we did see some survey data that suggests clothing worn will change  
19 over the season. And the survey data were temporal based on  
20 formulation type. And we only have percents with respect to  
21 application type.

1           So even though, normally, we would have -- in our typical  
2 screening level assessments we would use the short-sleeve shirt, short  
3 pants. And those we've already determined to be log normal. We  
4 would use a mean or some other statistic. But in this case, since we  
5 have in some case two application types which we may need market  
6 data for, we have a sense that as time changes, people are going to  
7 shed off a few clothes while they're making those applications.

8           We had a little bit of difficulty really trying to wrap my mind  
9 around that, so I took the flag of convenience of a uniform  
10 distribution. And I don't know if it really is going to make that much  
11 of a difference in this assessment. I think with a view towards the  
12 type of the data that we may be getting where you're going to actually  
13 have longitudinal survey information about what people wore while  
14 they made that application, then we can probably do a better job of  
15 developing distributions for those specific clothing types. But it will  
16 take many more files to load that into the model, so we want to make  
17 sure it's worth it.

18           Post-application becomes a little more difficult. It becomes  
19 more difficult to identify an activity pattern that is representative.  
20 Many years ago before this Panel some of you members may remember,  
21 we had an activity pattern or macro activity pattern as we would use in

21

1 this case called "Jazzersize" which would be a series of exercises on  
2 the floor or on the lawn in which you can roll around and do exercises  
3 that put you in pretty good contact with the treated area but for a  
4 short period of time.

5 It was a very reproducible study. It gave you very uniform  
6 results. The standard deviation would be less than the mean which  
7 was, you know, really great from a person designing a study, but it  
8 was really difficult to communicate to people what it really meant.

9 In the meantime, we decided to look at other studies which were  
10 a little more understandable anyway. So we looked at two studies, one  
11 with a spray and one with a granular formulation of choreographed  
12 activities but more believable kind of activities. They used crawling in  
13 one sense to mimic adults that still weed the old-fashioned way and  
14 edge or dandelions and things like that but also to perhaps mimic a  
15 child crawling, also playing touch football, Frisbee, things like that.

16 But there were activities like sun bathing on a blanket, which  
17 really are not all that intensive but perhaps maybe more representative  
18 of a picnic at a park or typical activities with the family on the lawn.

19 For children we took a look at a study that was done really as  
20 someone's dissertation. But it was a very interesting one that they  
21 used a nontoxic substance that's used to whiten shirts, other types of

1 clothing, safe. And you read with a short of a UV technology that  
2 measures florescence. And these kids were really nonscripted. They  
3 were just given toys and a half hour to just mess around, really, on a  
4 treated lawn. And that really seemed like a really valuable thing to  
5 also include with the children's transfer co-efficients.

6 So here they are for addressing post-application exposure. I  
7 should, also, add that we use the up to two hours and up to three  
8 hours -- well, two hours for adults and up to three and a half hours for  
9 children. The two hour value if the Exposure Factors Handbook. And  
10 that's actually time on a lawn.

11 There is a similar value for children, but with concerns about  
12 them being other places, other lawns, at the park, at the school, other  
13 places, I bumped it up to the three and a half hours so for time  
14 outdoors for that age group. But again that was a cumulative  
15 distribution based on the statistics and the Exposure Factors  
16 Handbook.

17 The adult transfer co-efficients range from 2,000 to 13,000. We  
18 used a uniform distribution. Again, you know, these are  
19 representative. Is it really what people do? Is it really something  
20 that's deserving of a log normal distribution? I'll leave that to the  
21 Panel.

1           And, also, for the children, you know, we're combining kids  
2           transfer co-efficients scaled down from the adults and, also, the  
3           inclusion of the nonscripted activities. You know, these may look like  
4           small numbers to most people, but they're fairly descent compared to  
5           what we've seen.

6           For the lawns, we have transferable residues. Often these  
7           studies are done in a number of locations. In this particular  
8           assessment, some we have a number of sites that are appropriate for  
9           the geographic regions. So we did a range of the distributions,  
10          uniform distributions, for values for each day that could include as  
11          soon as dry up to 8 hours, 12 hours after the application is made.

12          It, also, includes such factors as watering-in or not watering-in.  
13          And it also includes days that there's also the potential for rainfall.

14          And nondietary ingestion is even harder. Again, applying, that's  
15          pretty easy to measure. That's pretty easy to understand. What do we  
16          do on lawns? That becomes a little more difficult. And then what do  
17          kids do while on they're on lawns, hand-to-mouth behavior, it becomes  
18          even more elusive and difficult for us to address. It's very important  
19          pathway, obviously.

20          So we looked at a number of things. We looked at, first of all,  
21          frequency, which is based on observational data. But that really

24

1 doesn't tell us very much about how much gets on their hands. So we  
2 had to think about how much gets on hands by looking at some data  
3 that was done on behalf of ORD for this particular aspect. Also, how  
4 much comes off once it's on the hands.

5 Now for the hand-to-mouth frequency of events we continue to  
6 rely on Reed. And this includes 20 kids in day-care and 10 at home. I  
7 selected a uniform distribution of .4. I guess one can obviously say 1  
8 to 26 would be a little bit better. But in that study, the mean was nine  
9 and a half; median was eight and a half; and the 90th percentile was  
10 20.

11 Some issues for consideration is the differences in  
12 hand-to-mouth behavior that may happen when we're indoors or  
13 outdoors and, also, the differences between active and quiet play. I  
14 know this Panel has touched on this before. And just to go even  
15 further into discussion, some recent information that Dr. Freeman has  
16 looked at. Again, a small subset of children, but there's differences  
17 between the indoor and outdoor frequencies of hand-to-mouth events.

18 Now, if their mouthing, the hands are wet. So we wanted to  
19 make sure that we accounted for perhaps the increased transfer to the  
20 hands if the hands are wet. There was a comparison of wet-hand  
21 efficiency and dry-hand efficiency with three surrogate compounds.

25

1 And it was very helpful that these data had a very similar transfer  
2 efficiency as the available data that we have.

3 The turf-transferral residue data that we have measurements of.  
4 The range there was .9 to 3 percent for two chemicals. And we  
5 noticed that the chlorpyrifos was much, but it showed the same  
6 percent transfer.

7 So we would take the turf-transferable residue and increase it  
8 one and a half to three times higher to account for the hand-to-mouth  
9 behavior.

10 Now once the hand goes in, how much comes off. And that I  
11 think that's also fairly difficult to look at. One study by David  
12 Camann showed 50-percent removal by saliva-wetted sponges. And  
13 this struck us a sort of a vigorous wiping method. So we used that as  
14 our high value.

15 There was, also, another study in which people grabbed test  
16 tubes that were spiked with a know concentration and then a more  
17 passive sort of removal technique of hand wash with ethanol and with  
18 water was also used and they recovered 20 to 40 percent of that which  
19 is spiked on the hands.

20 And then, also, since outdoor play may also include, you know,  
21 residues and grass stains and smashing into the soil, you're going to

1 have kind of gamish of soil and residues. And so took a look at  
2 soil-removal data in which people had a certain amount of the soil on  
3 their hands and they measured how much was removed from various  
4 mouthings events, thumb sucking and the like. So that's kind of the  
5 basis of the removal efficiency for the hand-to-mouth.

6 Getting into golf, that's a little bit easier. But for the percent  
7 of individuals, we looked at a study that has statistics on the percent  
8 of people that play golf also the number of hours playing golf. I mean  
9 I pretty much left it for four, unless there was some indication that  
10 only greens were treated and then two to four hours. I didn't really  
11 mess around with that too much.

12 The percent of golf courses that were actually applying those  
13 pesticides is available, you know, in proprietary-type data available in  
14 Doane very recent. And this is also an activity pattern that is pretty to  
15 understand. You can just put people in dosimeters and go out and  
16 measure after they played golf on a treated golf course. That's a lot  
17 more easier to understand than what kids do and adults do when  
18 they're playing on lawns.

19 Although with it being that easy, you'd think there'd be a little  
20 more data. But we were able to get round 10 transfer co-efficients  
21 that addressed the playing golf, walking around, using a cart. There

1 really wasn't that much difference. Typically, fairways and the greens  
2 are treated. So if I guess if you're a duffer, you have less exposure if  
3 that helps anyone when they're having a bad day on the course. Again,  
4 we use chemical-specific turf-residue data.

5       Public health gets back into the difficult. And that is, you  
6 know, how much gets on the lawn from these applications. In the  
7 single-chemical assessments, the reviewers relied on information for  
8 how much actually deposits on to a lawn as a percent of the  
9 application rate. And that ranges considerably, depending on ground  
10 equipment, whether or not it's being applied by aircraft, you know,  
11 nozzle size, all those kinds of things, how much is evaporating. So we  
12 used that just to get a concentration to the lawns.

13       And once we had our deposition on the lawns, then we pretty  
14 much addressed it the same way we would a lawn chemical with the  
15 same transfer co-efficients, same hand-to-mouth values that we used  
16 and I just discussed previously.

17       To determine the number of population, we looked at statistics  
18 suggested how many people have lawns. When these things are  
19 applied, we spoke to people responsible for making these applications.  
20 And, obviously, part of the comment period we are certainly expecting  
21 a lot more information: Where, when, how, and why these things are

1 being used.

2           Now garden, again, this is pretty easy to understand.  
3 Application, and we have a number of studies to address the uses. We  
4 have a chemical-specific. For disulfoton we used a shaker can and this  
5 is just a systemic insecticide so you apply it to soil, rake it in, and it's  
6 great for roses and those types of things. We also have used the  
7 garden duster for vegetable gardens and also small tank sprayers for  
8 gardens and spraying trees and those types of things.

9           It has the same issues with the types of clothing. You start with  
10 long-sleeve shirt and long pants and as the season begins. And as  
11 summer progresses, you find yourself wearing less and less. But,  
12 again, to address that, we simply left it with the uniform distribution  
13 for this time.

14           The area treated for gardens, this was a fairly difficult to  
15 determine. So we simply used a median home area and assumed a  
16 certain perimeter. But in this case, we made sure that whatever the  
17 area that was treated, everything was treated. We didn't really make  
18 any distinctions there.

19           Vegetable gardens there was data suggesting it was log normal.  
20 There was a survey conducted by the Outdoor Residential Exposure  
21 Task Force with the Gallup Survey people. Vegetable gardens are a

1 little bit easier for people to understand, how big it is versus their  
2 lawns which is obviously complicated by the structures and green  
3 spaces and shrubs and trees and those sorts of things. And we went  
4 ahead and used a log normal for this statistic of garden sizes.

5 Now post-application dermal exposure, that, again is a pretty  
6 easy thing for us to understand in the agriculture region anyway.  
7 Someone is going to pick apples all day; that's great. The problem is  
8 when you get into home garden there's a certain number of crops that  
9 people have. There's a number -- they'll have trees. They'll have  
10 strawberries. They have grapes.

11 So, you know, with that, knowing there's so many difficulties,  
12 we just simply selected a uniform distribution that would represent a  
13 number of activities. And it includes hoeing and weeding, harvesting,  
14 staking tomatoes, picking apples, those kinds of things.

15 The duration of garden activities, survey data suggested five  
16 minutes to an hour, a couple days a week. But we went ahead and set  
17 it for every day.

18 And we also have a chemical- and regional-specific residue data  
19 which would most importantly impact the dissipation and how long it's  
20 actually in someone's garden.

21 For inhalation, for the indoor use of DDVP, we have standard

30

1 work horse, unit exposure from the pesticides handlers exposure data  
2 base. We just simply used the uniform range there.

3 For post-application inhalation exposure for adults and  
4 children, we had the pest strip data. But then, again, that use is no  
5 long registered. Crack and crevice from Gold. These aren't the most  
6 recent studies in the world, but they are what we have available to do  
7 this assessment with.

8 The duration of time spent indoors and breathing rates, we used  
9 readily available statistics in the Exposure Factors Handbook,  
10 obviously, up to 24 hours. And we used rest to moderate breathing  
11 rates.

12 Just simply, we discuss the majority of the data that we used for  
13 the major uses in this assessment. For example, we have the lawn  
14 residue data for all the compounds, and we made regional adjustments  
15 where feasible. We addressed a wide varieties of activity patterns.  
16 Some are more straight forward. Application, that's pretty easy. But  
17 it gets more difficult as you get into post-application in lawns, and the  
18 hand-to-mouth is still proved to be difficult for us to address.

19 And if it wasn't clear in my presentation, I'll simply say now that  
20 we tended to use uniform distributions our flag of convenience when  
21 we were presented with scenarios that had a lot of confounding

31

1 variables and it was a little bit difficult for us to address.

2 Now to characterize, again, for us the hose-end data, there's a  
3 lot of replicates. And we have the mix-your-own and ready-to-use.  
4 So, you know, we think that's pretty realistic with some further  
5 thought, you know, on developing distributions of the types of  
6 clothing that we have indicated by the survey or, you know, some  
7 other way to really handle that. You know, perhaps determine what  
8 percent of people are applying understand a certain clothing scenario  
9 and develop distributions for that.

10 For the push granular, 30 replicates of, again, high confidence.  
11 And these studies were performed by people that, you know, they don't  
12 work for chemical companies. These are just regular people that  
13 belong to garden clubs. So those type of people are recruited and they  
14 just went and did what they did without any coaching.

15 The lawn size, you know, is fairly reasonable considering the  
16 equipment used. It might be a slight underestimate in areas that have  
17 larger lawns. You really would be a deal breaker wouldn't have a huge  
18 impact on the assessment to make that variable larger.

19 For post-application on lawns, we do have activities that are  
20 representative. But, you know, the distributions may really reflect the  
21 study design rather than the actual activities. We are really more

1 interested in if we had a realm of activities that are representative or  
2 that can at least cover some of the other things, say, if you're just  
3 walking across the lawn. We were fairly confident that these cover  
4 things that are less than that. And, again, it seems like a reasonable  
5 suite of activities that people might be doing.

6 For the children, again, we have a combination of scripted  
7 activities. And then also there are unscripted activities, just kids  
8 being kids hanging out on the lawn. So we feel pretty good about that.

9 We have turf-transferrable residues. And it reflects a range of  
10 high values immediately after. But it also, you know, in the real  
11 world, it does rain and that's also a possibility on the second or third  
12 day or so after application.

13 The turf-residue hand-to-mouth, it's based on surrogate data; so  
14 there is some uncertainty there. It would really be a whole lot nicer to  
15 have chemical-specific data on that.

16 The frequency is, you know, it may be an overestimate; it may  
17 not. But, again, these are based on kids indoors, so there may be  
18 differences with kids outside.

19 Duration on lawn, for kids, again, we bumped up the value to  
20 beyond the times they spent on lawn. If the lawn was treated, you  
21 were reentering. So that's an aspect of this assessment.

1           For public health, it's a distribution of -- the uniform  
2           distribution of aerial ground equipment values. The percent of  
3           applications made by ground equipment and aerial. The population  
4           exposed to the public health we limited it to those having lawns and,  
5           you know, those having kids.

6           For the home gardens, you know the applicators, again, high  
7           confidence. Again real people making applications. The same deal  
8           with the home gardener and the granular application as well.

9           The garden, that area treated was pretty descent. We thought a  
10          pretty decent survey data. And, also, an outfit that's been collecting  
11          this kind of data for a long time.

12          Vegetables, you know, certainly a well-studied variable for  
13          individual crops. It gets a little complicated when you realize that in  
14          gardens people don't just have one thing. And it's a pretty high  
15          available exposure scenario.

16          Frequency applications. For frequency for the applications,  
17          again, you know, we used survey data. That's based on generic  
18          insecticides and it's not chemical-specific.

19          The post-application in the garden. We're assuming all the  
20          plants are treated. What it would also be reasonable to assume that  
21          you're only going to treat certain crops, certain types of year, certain

1 pests, that sort of thing.

2 The residues, we're pretty confident with those. Again, they're  
3 regional chemical-specific.

4 The indoor air is chemical-specific.

5 The duration, breathing rates, those sorts of things are pretty  
6 well-established factors in the Exposure Factors Handbook.

7 The population exposed, for the pest strips we based it on the  
8 use of all pests strips including those sort of hideous sticky strips that  
9 just catch flies. And the use patterns for all scenarios were based on  
10 the percent of households that were actually using that particular  
11 pesticide.

12 So, you know, now we're going to get into survey data. And  
13 that, also, presents, you know, a number of possibilities. So we're  
14 going to, first of all, look at how, you know, how we put people  
15 together in our assessment. And then, also, just by way of example,  
16 what one might do with survey data. And also to discuss a little bit  
17 about the upcoming pest use survey data that was discussed just this  
18 past Tuesday.

19 So survey data, you know, primarily to look at what they would  
20 like to call "human activity patterns." And these are macro activity  
21 patterns. This is, very simply, in the garden. Obviously, that's a

35

1 macro activity pattern. And the types of transfer co-efficients are  
2 macro activity based. You know, driving to work, time at school,  
3 those sorts of things, you can track an individual during the day.

4 But our basic approach for this assessment was kind of an  
5 independence/dependence. First of all, we identified households based  
6 on their reported use of an OP for a given scenario and relied pretty  
7 heavily on the National Home and Garden Pesticide Use Survey. For  
8 example, 6 percent of households in Region 5 used lawn chemical A.

9 Then we identify, from the Exposure Factors Handbook, how  
10 much times do people spend on lawns. And those values were taken  
11 from surveys such as the National Human Activity Pattern Survey, a  
12 pretty large cohort survey. Not necessarily addressing the use of  
13 pesticides. I think it was primarily designed for addressing  
14 secondhand smoke. But, again, it was useful as far as where people  
15 spend their time.

16 So in our simple step-wise process, you have your food  
17 exposure calculated from DEEM. And then you would select the  
18 residential treatments for an individual on a given day; and this, of  
19 course, is regional-specific. You know, where the pesticides applied  
20 are in or around the home, and if so, what are the treatments, what are  
21 the frequencies.

1           So that's why it was really important that we had that early  
2           matrix be the windows of exposure possibilities. So for each day, as it  
3           works its way through the year for each individual, it is going to go  
4           does this house, a certain percent of houses are using a pesticide. And  
5           so it will pick statistics from those libraries that have all those  
6           exposure values for that scenario. And you'll just keep repeating this  
7           step until you've addressed all the uses that are available, again, going  
8           back to that large matrix.

9           So for this assessment, co-occurrence is driven just by random  
10          probabilities. So, again, largely the percent of the houses being  
11          treated. So 6-percent lawn use, 10-percent crack use will give you a  
12          certain percent that has both. And, again, we just want to stress,  
13          whatever household is selected, the probability of -- you know, you're  
14          going on that lawn and you are in that house. So we don't really mess  
15          round with, at this point anyway, of looking at the people who  
16          responded that they didn't go on the lawn. But there is data that  
17          suggests that people just don't exactly go running right out there. But  
18          for this assessment, if you have a lawn and if you have a lawn chemical  
19          applied to your house, you're going out there.

20          So now this very nice new web site that's available to us all, the  
21          Consolidated Human Activity Data Base. There's a lot of survey data

37

1 that's suddenly available to us all. And it's a compilation of lot of  
2 human activity pattern surveys. So you can look at the questionnaires  
3 and you can look at the responses. So there's now the possibility that  
4 you can develop a daily activity patterns for individuals. You can kind  
5 of track their life in a given day.

6 But, again, these surveys are mostly cross-sectional and they're  
7 not longitudinal. We do expect a pesticide use longitudinal survey one  
8 of these days from the regulated community.

9 And with all apologies to Drs. Zartarian, Xue, and Ozkaynak, I  
10 just pinched a couple of their slides that suggest, just by way of  
11 discussion, a strawman, if you will, and how one could approach using  
12 survey data.

13 And this would be that you could get individuals and track their  
14 time. So you could actually identify how much time they spent in a  
15 given room. And this may be important for the crack and crevice uses.  
16 It could be important for other uses of pest strips if it's simply being  
17 used in a garage or something like that. You know, how much time  
18 did they spend on the lawn. Those sorts of things. So you have an  
19 accounting for all the time they spent in the day.

20 And then possibly you could assemble diaries that would  
21 simulate a person. You could use a number of surveys to address what

1 they might do seasonally, what they might do on the weekends. And I  
2 would imagine that we would have to also somehow tie it to the type  
3 of person that we also selected from the CSFII. So, again, this is just  
4 the kind of thing that's going to be available for us to address perhaps  
5 this assessment, perhaps more likely future assessments.

6       You know, finally, the Residential Exposure Joint Venture is  
7 collecting data longitudinal in nature that actually address the  
8 application of pesticides in and around the household. We're going to  
9 have information on when and where the applications of specific active  
10 ingredients are made. We're going find out whether or not multiple  
11 applications are made.

12       In our scenario, it might be very likely that, based on the  
13 application treatment type, you could treat your garden and your  
14 ornamentals in one day. It would be nice to have survey data that  
15 suggested that that is exactly what people did.

16       I think what's really important is we also have what they wore  
17 while they were making those applications. So it would make our  
18 management of those log normal distributions of clothing scenarios a  
19 little more of a fit for the seasonal aspects. And it's also going to  
20 discuss the demographic information. Do they have children? A lot of  
21 people who garden are a little bit older, the kids are gone, and they

39

1 need something to do, so that isn't necessarily figured into this  
2 assessment. But that might be something that may be of importance in  
3 future assessments.

4 So with that, I'll conclude my presentation and would be happy  
5 to answer any questions of clarification.

6 DR. ROBERTS: Thank you, Mr. Evans. Are there any  
7 questions from Panel members clarifying from your presentation or  
8 your methodology?

9 DR. BULL: This is probably in here, but I was not able to find  
10 it nor did I catch it out of your presentation.

11 You got these transfer co-efficients in turf-transferable  
12 residues. Transfer efficiencies is kind of different unities that you go  
13 after this. But I didn't see -- is, say, dermal absorption included in one  
14 of those? I saw no mention of the absorption rates.

15 MR. EVANS: Yeah, a lot of times we do, obviously. But in  
16 this case, our endpoint is from a dermal study; so we have made no  
17 adjustment.

18 DR. BULL: But how do you relate that to the amount that's  
19 absorbed from the area that's exposed?

20 MR. EVANS: Do I have that data?

21 DR. BULL: That's what I'm trying to ask.

40

1 MR. EVANS: Well, the endpoint or the effect is based on a  
2 dermal application to the laboratory animals.

3 DR. BULL: I see. Okay.

4 MR. EVANS: But a lot of times we have endpoints from oral  
5 studies that we do.

6 DR. BULL: So it's purely empirical.

7 DR. ROBERTS: Dr. McConnell.

8 DR. MCCONNELL: Yeah, a quick question. Are these  
9 different procedures you're described to us today written out in SOP  
10 form, and are they available?

11 MR. EVANS: The --

12 DR. MCCONNELL: How you --

13 MR. EVANS: How do we calculate all those things? Those are,  
14 first of all, our standard operating procedures for residential exposure.

15 DR. MCCONNELL: For how you collect this material, are  
16 those in form of a standard operating procedure?

17 MR. EVANS: We have a standard operating procedure for how  
18 to make the calculations. And we also have guidelines on how to  
19 conduct those studies to get those --

20 DR. MCCONNELL: That's what I'm more interested in.

21 MR. EVANS: Yeah, very much so.

41

1 DR. MCCONNELL: Okay.

2 MR. EVANS: I believe some members of this Panel actually  
3 may have been on a guideline-related subject.

4 DR. MCCONNELL: I recall the guidelines for post-application.

5 MR. EVANS: Yes.

6 DR. MCCONNELL: But that's the only one I recall. There are  
7 guidelines for other things.

8 MR. EVANS: Right. Not this Panel, but previous panels have  
9 addressed the application aspects as well.

10 DR. ROBERTS: Dr. Durkin then Dr. MacDonald.

11 DR. DURKIN: I see that you cover the public health use of  
12 chemicals in that sort of indirect sorts of exposure. What I didn't see  
13 -- and I may have missed it -- did you address pesticide exposures to  
14 populations that live close to or adjacent to agricultural areas? You  
15 know, cotton fields, tobacco --

16 MR. EVANS: No, we did not.

17 DR. DURKIN: Okay.

18 DR. MCCONNELL: Isn't that your spray drift?

19 DR. ROBERTS: I'm sorry. Dr. McConnell.

20 MR. EVANS: I believe you're referring to spray drift.

21 DR. DURKIN: Drift from agriculture.

42

1 MR. EVANS: Right.

2 DR. MCCONNELL: Excuse me for interrupting, but they have  
3 guidelines on how to measure spray drift.

4 DR. DURKIN: No, I'm not talking about how you measure  
5 drift; I'm talking about those populations who their residence is close  
6 to an agricultural area where pesticides may be applied over the course  
7 of the season, so folks living next to tobacco fields, cotton fields. I  
8 know they have methods to get at the drift. I wanted to find out was  
9 that drift factored into the risk assessment.

10 MR. EVANS: No.

11 DR. ROBERTS: Before we get to Dr. MacDonald's question,  
12 let me remind the Panel that our proceedings are being audiotaped; and  
13 it will be very use for someone listening to the tape if they can sort of  
14 make sense in terms of who's commenting. So if I haven't just called  
15 on you or it's not otherwise obvious who's making the comment, I'd  
16 appreciate if you could just briefly state your name before we dive in.  
17 And that way, we'll be able to sort it out later on.

18 Dr. MacDonald then Dr. Bull.

19 DR. MACDONALD: Just a couple of questions. Very clear  
20 presentation. But 4-19, Lawn Applicator Exposure Data, you said you  
21 selected a uniform distribution. It's not clear what this is a uniform

43

1 distribution for. What's the variable being considered there?

2 MR. EVANS: You unit exposure is the metric that describes  
3 how much gets on you on a per AI basis on the amount of AI used.

4 DR. MACDONALD: And, also, considering that you've  
5 accounted for the amount of clothing worn, but do you also consider  
6 what happens to the clothing afterwards? They'll come into the house.  
7 They'll sit on furniture. It will be handle by someone doing the  
8 laundry. So I don't think wearing clothing is necessarily the end of it.

9 MR. EVANS: Yeah, I mean, that's true. There's a number of --  
10 I mean pesticides migrate. That we do know. But how do we actually  
11 model that is really difficult. We're really focusing right now on what  
12 we sort of think of as "big ticket items," the actual handling of the  
13 concentrate. That's certainly one aspect.

14 Probably over the course of -- at least my experience in this is  
15 that, you know, our guidelines are not -- you know, they're  
16 conditional. So we've always had a sort of step-wise view of things.  
17 The old days of agricultural applicators were okay, you know, in even  
18 probably home garden people were. But as time goes on, we get more  
19 sophisticated; we ask more questions.

20 For the residential, we're beginning to become comfortable with  
21 the application or beginning to come a little more uncomfortable with

44

1 post-application. But some of the more elusive and arguably smaller  
2 concentrations of pesticides that's still on the horizon for us to  
3 consider.

4 DR. ROBERTS: Dr. Bull, do you have a questions Mr. Evans?

5 DR. BULL: Just a quick. The past question about public health  
6 spraying brought up a question in my mind. That at least in some  
7 geographical areas lawns would not be sprayed for that purpose. I  
8 don't know how wide sprayed it is that you spray residential areas in  
9 other parts of the country. But where I am, it's most likely the guy  
10 that's got his kids on the boat running up and down the Yakima River  
11 that's going to be exposed rather than someone being exposed on the  
12 lawn.

13 I'm a little bit worried about the issue of identifying lawns as  
14 the major determinate of exposure for public health spraying. It  
15 actually might be drinking water exposure in some cases because that's  
16 the drinking water source, too. so I'm questioning that a little.

17 MR. EVANS: Right. Again, just thinking how we approach  
18 some of these things. There's an infinite number of exposure  
19 scenarios. But if it is applied to one's lawn and then goes out and  
20 performs activities, that's a pretty good hit. I think a random flyby is,  
21 you know, in my view, a little less of a potential.

45

1 DR. BULL: No, it's deliberately done in specific areas, not in  
2 lawns; that's what I'm worried about. Along the river, for example.

3 MR. EVANS: Right. I mean you're suggesting more of a  
4 refinement of our assumptions.

5 DR. BULL: Yeah. It may be true for the nation as a whole; but  
6 certainly in the area I'm in, it would not be sprayed over residential  
7 areas.

8 MR. EVANS: Right. I think I could say, fortunately, that none  
9 of these are used from a public health perspective in Manachi, Yakima  
10 area, the Washington area

11 DR. BULL: Tri-city area, yes.

12 MR. EVANS: Yeah. At least to my knowledge, these are used  
13 more in Florida, East Coast, you know, places like that down in the  
14 south. At least these pesticides are used in this respect.

15 DR. ROBERTS: Dr. McConnell.

16 DR. MCCONNELL: I just wanted to state that Dick lives in an  
17 unusual area. My neighbor, for instance, he subscribes to one of these  
18 outfits. And seven times a year, they're putting something on his yard.  
19 And, in fact, they put a little sign up to let you know when you've been  
20 there so that you don't let your pet run over on their yard. I mean in  
21 the neighbor I live, this is about every second or third yard has one

46

1 ever these signs in it, seven times a year. So this is not unusual at all.

2 DR. BULL: Not unusual in North Carolina.

3 DR. ROBERTS: Dr. Adgate.

4 DR. ADGATE: I just want to make sure I've got this straight.

5 And as I've been thinking about this, and it's a very good presentation.

6 The question I have: This model as we look at this and try to fit  
7 all the pieces together is essentially cross-sectional. Right? You can  
8 -- I'm worrying about you got a bunch of different scenarios and how  
9 is it constrained so if you have a lawn you're more or less likely to  
10 have a garden, I would assume. And there's certain things fit together  
11 and certain things you wouldn't as you look at this. And I'm  
12 wondering how the model deals with that particular issue.

13 MR. EVANS: Yeah. We deal with it totally randomly at this  
14 point. So the percent of houses that use this pesticide on the lawn,  
15 you know, you're going to have a certain odds there. And just totally  
16 independently, you're going to have a garden.

17 DR. ADGATE: So there's no sort of correlation made --

18 MR. EVANS: Right. That's why the type of data that's bandied  
19 about every once in a while about the longitudinal, what people  
20 actually do, that would really be the key to really identify that  
21 co-occurrence. Right now, it's just kind of a roll of the dice.

47

1 DR. ROBERTS: Any more question before we move to public  
2 comment? If not, thank you very much, Mr. Evans, for a very clear  
3 presentation.

4 We have two individuals who've indicated an interest in  
5 addressing the Panel on this subject. One is Dr. Jeffrey Driver, from  
6 infosciencs.com. Dr. Driver. Welcome. Can you introduce yourself  
7 for the record?

8 DR. DRIVER: Good morning again. I'm Jeffrey Driver with  
9 infoscientific.com. I'm making some comments this morning on behalf  
10 of the Implementation Working Group, but also beneath that  
11 Residential Exposure Joint Venture, the group conducting the survey  
12 that Jeff mentioned, the temporal survey; also a group called Sound  
13 Science Policy Alliance that represents some of the OP manufactures.

14 A very good job, Jeff. And I have a theory that some of our hair  
15 loss may be associated with this cumulative risk assessment.

16 The comments that I want to make this morning really reflect my  
17 position and I think the position that I think many of us share. If you  
18 want to make comments, you should also be part of the solution. So  
19 some of the issues and next steps that I'll be suggesting are things that  
20 EPA has already recognized, is addressing, and also other stakeholders  
21 are addressing.

1           Some of the issues, I think, also as I'll point out, are work in  
2 progress or things that we need to do in the future. But I'll try to  
3 distinguish those.

4           I think, as Jeff's given you an appropriate impression of the  
5 complexity of residential exposure analysis. It's truly multi-route,  
6 multi-pathway issues of interdependence or dependence versus  
7 independence rather, conditional probabilities. There's a lot that we  
8 don't understand. We're ostensibly trying to simulate human behavior  
9 across time. So we're all sort of residential experts in some sense and  
10 we all have an appreciation for the dynamic of that.

11           So you know, again, as Jeff said, we try to keep it simple but  
12 with the caveat that all models should be as simple as possible but no  
13 simpler. So I think that's kind of the state of the science and the  
14 challenge that we face.

15           What I'm going to do quickly is just give you a quick overview  
16 of some of the issues, next steps. First under the rubric model input  
17 and output quality assurance review. As Jeff mentioned, some of these  
18 issues have already been recognized. So I won't belabor some of it.

19           Label application rates, just checking our accounting system,  
20 making sure things are correct. Product-use scenarios, Jeff mentioned  
21 there's kind of an ongoing understanding of what's registered and

49

1 what's not. I give an example of a scenario that is not registered as we  
2 understand it, but it is included.

3 Exposure duration corrections at some of the upper percentiles.  
4 It appears that we have greater than 24 hours per day for some  
5 individuals. That is, they might be spending 24 hours inside the home  
6 maybe inhaling DDVP and then they go outside and spend a couple  
7 hours on their lawn. That's another quality occurrence check.

8 The evaluation of the impact of alternatives of uniforms  
9 distributions under the guise of sensitivity, you know, as Jeff has  
10 requested the Panel's advice in this regard, I think we do have some  
11 opportunities to explore distributions other than uniform, which, of  
12 course, assumes that every value within that range as an equal  
13 likelihood of occurring. Most data sets have some shape and some  
14 inferred probability at the upper and lower tails, typically, of  
15 occurrence.

16 So, you know there are some examples that I mention there.  
17 The hand-to-mouth, I'm particularly interested in. And I'm hoping  
18 Natalie and others can give us some advice there. We mentioned the  
19 indoor versus outdoor differences.

20 The unit exposure distribution as Jeff indicated, we have some  
21 fairly good data sets for those. This is getting an applicator exposures

50

1 for different methods of application, clothing configurations. I think  
2 that's a ripe opportunity there.

3 We, also, recommend that EPA and other groups for that  
4 matter, too, really investigate this temporal product use and single-day  
5 co-occurrence prediction. As Jeff mentioned, you know, what we have  
6 is a predictive algorithms that allow us to do this. But I very it's very  
7 important that we have explicit understanding. I challenge us to do  
8 this.

9 We need to understand how the algorithm is structured and is  
10 working. And very importantly, what's the interpretation quality of  
11 the underlying data. For example, Jeff mentioned this generic sort of  
12 general market share values by scenario. What's the percent of uses  
13 versus non-users in the U.S. that use lawn-care products.

14 But underneath that, there are other conditional probabilities  
15 that John Adgate was sort of getting at. For example within, you  
16 know, this general market share, what's the relative market share of  
17 using one OP versus another. If you have multiple OP products that  
18 could be used for the same scenario, say, to treat the lawn, which one  
19 do you pick within that group?

20 There are other examples of conditional probabilities. You  
21 know, if you have a lawn, is there an associated likelihood that you

51

1 also have a garden, a vegetable garden.

2 The REJV survey and other survey data I think allow us to get  
3 at some of those conditional probabilities that otherwise we have to  
4 kind of piece together as a patchwork quilt from various data sets.

5 Timing and frequency of application by region. I think as Jeff  
6 pointed out, why do people use pesticides? That's kind of where we  
7 have to start. You know, you're managing pest population dynamics  
8 which, of course, can change from year to year. But, again, temporal  
9 survey information, I would submit, is what we really need to  
10 understand this in a realistic way.

11 Explanation of the peak exposures observed in graphical  
12 outputs. I'm sure you all looked at these three 65-day plots of  
13 different percentiles. And, of course, those each day might be a  
14 different person. You know, it's a 99.9-, 95-percent person  
15 represented at that percentile. And sometimes you'll see peaks and  
16 features in these plot schemes.

17 Well, understanding what's driving those peak exposures, what's  
18 the underlying demographic of that individual, their activity pattern,  
19 the scenarios involved that are driving their residential assessment;  
20 you got to really investigate those peak exposures. Obviously, they  
21 have important regulatory implications.

1           That kind of leads to the next theme of contribution sensitivity  
2           and uncertainty analyses. And I think, again, under the guise of sound  
3           science, transparency, stakeholder involvement, we have an obligation  
4           to pursue this, to give our risk managers the best information and  
5           advice we can.

6           One of the things that concerns us is I think EPA, and we have  
7           an obligation as well as others of us who are interested in, evaluating  
8           the biological plausibility and statistical representativeness of some of  
9           these upper percentile values. Are there people who are spending  
10          more than 24 hours in the day? Are they consuming, you know, if you  
11          look at the dietary, same issues really apply. Are they consuming  
12          plausible amounts of foods? So are the combinations of various input  
13          values resulting in simulated people who are understandable and within  
14          the realm of reality.

15          Meaningful drill down. As I implied with the previous slide,  
16          contribution analyses. Trying to figure out what's driving these peak  
17          values or for any given person or population strata, what chemicals are  
18          contributing, sources, scenarios, lawn care, garden, et cetera, even  
19          which specific products they're using. Which specific OP product  
20          they're presumably using, pathways and routes.

21          This type of uncertainty contribution sensitivity and uncertainty

1 analysis, I would submit, is really needed prior to determination of an  
2 appropriate percentile regulation. I mean, what confidence do you  
3 have at what percentile that you're looking at. I think you've got to  
4 establish that before you can really decide on a percentile regulation.

5 I'd also submit that you need these analyses, again, for  
6 meaningful risk management. If you're going to do mitigation, you  
7 really have to decide what you're mitigating. You know, what  
8 products are involved, what scenarios are involved. Particularly with  
9 the residential, you know, again, it's a variety of inputs that create this  
10 exposure estimate. So we've got to be able to drill down. We can't  
11 just look at methamidophos equivalents. We have to drill down to  
12 figure out if mitigation is necessary and what it would be.

13 An issue that has been raised previously that I think deserves  
14 careful consideration is what's the most appropriate exposure metric.  
15 We're looking at route-specific exposures right now, external  
16 exposures, and comparing them to methamidophos benchmark doses  
17 and going through relative potency factors. That's fine.

18 Another alternative altogether is to look toxic equivalent dose  
19 in terms of total absorbed dose. With the current situation, we're  
20 looking at route-specific external exposure and comparing it to some  
21 bench route specific benchmark dose, should we be looking daily

54

1 exposure metrics or should we be looking at some time averaging,  
2 moving average metric.

3 And I think that's if you look at the underlying kinetics and I  
4 think the Panel can hopefully give us guidance in this regard, what  
5 should we be exploring in that situation. I think there's a relevant  
6 opportunity to look at some type of moving average here.

7 Finally, it's important, you know, for all of us to review and  
8 participate in and also review the upcoming revised version of the  
9 cumulative risk assessment.

10 Thank you very much.

11 DR. ROBERTS: Thank you. Are there any questions for Dr.  
12 Driver? I don't see any, so thank you very much.

13 The second individual who's requested the opportunity to  
14 address the panel is Dr. Judith Schreiber from the New York State  
15 Office of the Attorney General.

16 Welcome, Dr. Schreiber, and could you, also, introduce yourself  
17 for the record.

18 DR. SCHREIBER: Certainly. Good morning. Nice to see you  
19 again. I'm Dr. Judy Schreiber, senior public health scientist with the  
20 New York State Office of the Attorney General.

21 Again, a very commendable effort by EPA and certainly a very

55

1 clear presentation. These are clarifications and questions,  
2 observations I had during the presentation. My office will be  
3 submitting formal comments to the EPA on the cumulative risks.

4 The first question I had was with the regard to the pet products.  
5 It was mention, I believe, that that has not yet been assess but the  
6 intention is that EPA will be assessing exposure from use on pet  
7 products. Particularly, I'm concerned about potential children's  
8 exposure to hand-to-mouth activities in playing with their pets.

9 How does the EPA intend to assess this, and will the public have  
10 an opportunity to comment on that portion of the assessment prior to  
11 the document becoming final? That's one question I have. Should I  
12 just continue and --

13 DR. ROBERTS: Sure. Would you, please.

14 DR. SCHREIBER: Okay. Thank you.

15 Another question that came up. And I'm taking these in order of  
16 the presentation that the EPA made. What about inhalation exposures  
17 during the scenario of children playing on lawns? There was quite a  
18 bit of discussion about the rolling around and dermal absorption and  
19 clothing contamination that sort of thing. I think that's very good.

20 But I believe there could certainly be a possibility that the child  
21 might, also, inhale some of the material as they're rolling around with

1 their nose to the dirt in the grass and so for the. So I think that really  
2 needs to be assessed, at least a ballpark assessment of whether that's a  
3 significant contributor.

4 Also, ingestion of both soil and grass by young children is a  
5 common phenomenon. I know my kids were little they definitely dug  
6 around in the soil and often tried to put it in their mouths. Was that  
7 assessed with regard to the rolling-on-the-lawn scenario?

8 Another comment about the golf scenario which I thought was  
9 quite interesting. I've read a number of recent reports in the popular  
10 press in the popular press about increasing numbers of children playing  
11 golf. Tiger Woods has inspired a whole generation of kids to really  
12 like golf and go out there. And there's been a lot, I understand from  
13 my golfing colleagues, in golfing magazines they're talking about the  
14 increasing number of children and, also, the effort to try to include  
15 more children in playing golf.

16 So has there been any effort to assess the percentage of the  
17 population of children that might be actually on golf courses and  
18 potentially exposed to government treatment chemicals?

19 One particular area that I didn't hear and maybe I missed. It's  
20 possible it was included in another section. School exposures to  
21 pesticides, I didn't hear that mentioned at all; and I think that's

57

1 potentially a very large area. I know certainly in New York State we  
2 now have a pesticide notification regulation where schools that treat  
3 their indoor environments and their outdoor fields, soccer fields,  
4 football fields and so forth, have to notify parents. There's been a lot  
5 of concern from parents about potential exposures in school settings.  
6 And I didn't hear anything about that. But I think there probably are  
7 some data that are available that talk about the percentage of schools  
8 that treat either indoors or outdoors with OPs.

9         And I think it's a great concern to parents and especially for  
10 young children, are they being exposed to OPs in their school  
11 environments that could cause them to have undue exposures,  
12 especially for young children, but also for sexually maturing teenagers,  
13 I think that's probably equally an area of concern. And I didn't hear  
14 that discussed.

15         Two final points. One, although, I certainly understand the  
16 need for these mathematical manipulations, they're also a little bit  
17 troubling in some regards. For example, it was mentioned that -- and  
18 it might have only been an example but let me just carry it through.

19         For instance, 6 percent of homes and lawns are treated in a  
20 particular geographical location in the country. While that may be  
21 true and one can figure out what the overall average population

1 exposure could be if 6 percent of the lawns are treated. But if you are  
2 a child playing on that lawn, your exposure probability for that child is  
3 a hundred percent. That child is definitely being exposed. And I  
4 would like to see an analysis that in terms of the children who actually  
5 being exposed, how close is that child's estimated exposure to the  
6 point of departure for cholinesterase inhibition? How close is that  
7 exposure to the point of departure for neurotoxicity and  
8 neurodevelopmental effects. I think that's something that really needs  
9 to be looked at.

10           You know, if we take this room of people and only one of is  
11 exposed and we divide by the number of people in this room, well, then  
12 that number is very low. But if you're that one person who's exposed,  
13 you could be exposed to a very high level that can actually cause  
14 health effects. And I think that's a very serious oversight. At least in  
15 my reading of the documents, I haven't seen anything looking at that.

16           And then finally the public health uses. In New York State we  
17 have had experience using -- you have to forgive. I forget which  
18 chemical it. But for the control of West Nile Virus in New York State  
19 where there was quite a bit of public health spraying to control the  
20 mosquitos carrying West Nile. And we received a lot of residential  
21 complaints about inhalation exposures as well as concern about

59

1 exposures of lawns, gardens, and people because the spray would come  
2 down in areas where people were located.

3 And so I think that's a big concern that should be addressed  
4 even though it might be sporadic and it is necessary for public health  
5 protection, I think that's something that the EPA ought to consider.

6 Thank you.

7 DR. ROBERTS: Thank you, Dr. Schreiber. A long list of the  
8 questions. I guess, would the Agency like to respond to those?

9 MS. MULKEY: Well, I think that for most of this, that we will  
10 treat these as public comments. And we will be sure that we include  
11 them in our docket from these comments as well as from any that the  
12 Attorney General's office may subsequently submit.

13 I would say that if any of the issues give rise to questions in  
14 panelist's minds, we would welcome hearing that as you go through.

15 The only thing of this list that might be useful to spend just a  
16 few minutes on, because it comes up in a lot of context and I know  
17 that we've done some thinking about, is the school exposure situation.  
18 So, Jeff, if you just want to spend a minute on how we've thought  
19 through that issue. But beyond that, I think, in short of panelist's  
20 questions, we will treat these as public comments for our docket as  
21 well.

60

1 DR. ROBERTS: Thank you. Mr. Evans, did you want to  
2 respond to that one?

3 MR. EVANS: Right. I think, if I remember correctly and I  
4 know you always do a good job of refreshing my memory when it fails  
5 me. I think with the schools, we did look into the use of these  
6 pesticides, and we pretty much came up empty. Also for lawn uses,  
7 again, we stretched the time that someone could be on a treated lawn  
8 to include all time outside which, you know, at this point in time is at  
9 least a way to address time at school in which a soccer field or  
10 something like that may be treated.

11 You know, when we get a little more sophisticated and move  
12 people around in this model, we'll be able to do that. But right now,  
13 we just jam up all the time on the lawn to include the time at home and  
14 also time in other places.

15 DR. SCHREIBER: So I guess then you're assuming that the  
16 schools -- their use patterns will be similar to what the residential use  
17 patterns will be?

18 DR. ROBERTS: That was a follow-up question by Dr.  
19 Schreiber for the record. Go ahead, Mr. Evans.

20 MR. EVANS: Right. Right now, again, since we're not moving  
21 people around, we're just extending their time on a treated lawn to

61

1 account for other places.

2 DR. SCHREIBER: That would be a yes.

3 MR. EVANS: That would be a yes.

4 DR. ROBERTS: Let me just ask the Panel members if they have  
5 any questions for Dr. Schreiber or for the Agency in view of Dr.  
6 Schreiber's questions.

7 DR. HATTIS: Do you have any sort of documentation about  
8 insecticide use in school's day-care centers? I'm thinking of sort of  
9 cockroach treatments and things of that sort.

10 DR. SCHREIBER: I do believe that we could probably generate  
11 some. I think in New York State, because of the notification  
12 requirements, we probably do have some data that I could try to  
13 provide for the EPA. Sure. Thank you, Dale.

14 DR. ROBERTS: And Dr. MacDonald.

15 DR. MACDONALD: I'd just like to say the contact I've had  
16 with this work it still leaves me wondering why institutional exposure  
17 isn't taken more into consideration. I'm thinking back I think it was  
18 the Lifeline, for example, which was looking at the residential  
19 exposure but not institutional. And it was showing that when children  
20 started to spend more time hanging around in malls and schools and  
21 places, that their apparent exposure levels dropped. And I really had a

62

1 concern. Was that simply because the model wasn't taking into  
2 account the exposure they would find in the places they were hanging  
3 in.

4 MS. MULKEY: It may be helpful to remind all of us that many,  
5 though not quite all, of the organophosphate have been canceled for  
6 these public-setting uses. So the remaining compounds that lawfully  
7 used -- or will be at the relatively short time line -- are only those that  
8 are identified in this assessment. I need to make absolutely sure about  
9 that. But I'm pretty sure about that.

10 So we don't have a different group of compounds. And the  
11 number of compounds involved is now very small. Nevertheless, the  
12 rest of the answer was the one Jeff gave, that the attempt to have and,  
13 in fact, have home setting be a surrogate for the institutional setting  
14 by extending the time.

15 DR. ROBERTS: Thank you, Ms. Mulkey for that clarification.  
16 And thank you, Dr. Schreiber, for your comments.

17 Let's go ahead and take the first question under this section.  
18 Could you pose the question to the Panel, Mr. Evans.

19 MR. EVANS: I do have to confess. This is a little difficult for  
20 me so bear with me. I'll be visiting the eye doctor in two weeks. I'm  
21 at the trombone phase of reading large and small print. I'll do my best

1 here.

2 Historically, the Agency has relied on means (primarily  
3 arithmetic or geometric) from residue and exposure studies for key  
4 input variables in exposure assessments. The recent development of  
5 calendar-based models and others having features to incorporate  
6 distributions of exposure values has presented the Agency an  
7 opportunity to consider using all available data points from existing  
8 exposure and residue studies.

9 In the Cumulative Risk Assessment Case study presented to the  
10 FIFRA Scientific Advisory Panel in September, 2000, most of the  
11 exposure variables were presented as uniform distributions. The  
12 exceptions were for variables that are reasonably well established,  
13 such as exposure factors taken from the Agency's Exposure Factors  
14 Handbook.

15 The data used in the Case Study and the preliminary CRA are  
16 believed to be from well-conducted studies of generally high quality.  
17 However, these data sets tend to be small (e.g.,  $n = 10 - 30$ ) and are  
18 being used to address wide variety of exposure situations.

19 The uniform distribution appears to be the most appropriate for  
20 these relatively small data sets because it relies on easily established  
21 values such as the minimum and maximum and provides the most

1 conservative estimate of the standard deviation.

2 Does the Panel have any additional comments or thoughts on the  
3 OPP's use of the uniform distribution in general on OPP's selection of  
4 the uniform distribution of the specific parameters chosen? What  
5 criteria, if any, would SAP recommend for parametric input  
6 distributions from available data? Under what circumstances, if any,  
7 would it be appropriate to use available data empirically?

8 Does the Panel have any recommendations on how sensitive  
9 analyses could be performed to determine if the assumption of a  
10 uniform distribution is responsible for a majority of the risk at the tails  
11 of the exposure distribution?

12 DR. ROBERTS: All right. The first question is, of course, in  
13 fact, a lot of questions. Dr. Adgate, would you like to lead off the  
14 panel discussion on this.

15 DR. ADGATE: Fortunately, I have lots of answers or at least  
16 attempts at answers.

17 I want to say just in starting out a couple of things. This is a  
18 very nice presentation, and I got a much better sense having seen this  
19 presentation what this was about than I got if from reading the  
20 document. Clearly, there's a lot of things going on since that was  
21 written in December.

1           And I particularly like that table that though sort of lays out all  
2 the key assumptions and what you thought about their quality, the  
3 uncertainty associated with them. And I think that's an important  
4 thing that goes into the document in it's next iteration.

5           You know, that said, I think one of the things you're going to  
6 hear, I think, from a lot of us is problems with -- I mean we're the ones  
7 that told you to go and use the uniform distribution. Which brings to  
8 mind, the old analogy about when you have a hammer in your hand,  
9 everything looks like a nail.

10           And I think in this case, while the uniform distribution is a good  
11 idea, you know, it's the simplest tool you could use. And I think, as a  
12 group, we're probably -- I can't speak for everybody, but I suspect for  
13 conversations I've had with people that we're all going to sound  
14 something along the lines of you need to talk about characterizing the  
15 shape of the distribution based on even the sparse data that you have.  
16 So that's a quick summary of it.

17           We recommended the use of uniform distributions in the cases  
18 where data were sparse or uncertain. This is distribution which sets  
19 the minimum and maxima assumes each value within the range is  
20 equally likely and simplest model input. It's use is appropriate if you  
21 can -- which you seem to have done and all the values equally likely to

1 use as an analyst.

2 To me, a first step in a continuum as you move from a uniform  
3 distribution to a well-characterized distribution, in your question  
4 you're calling that fully parameterized or something along those lines,  
5 a well-characterized distribution based on large unbiased data sets.

6 As complex distribution, I think the next more complex is the  
7 triangular distribution. You can make use of here and make use of  
8 certain statistical testing techniques that will tell you something about  
9 shape that I think you could incorporate relative easily and that that  
10 would make your presentation of this fairly complicated model a little  
11 more convincing to me.

12 Changing from a uniform to a triangular distribution, for  
13 example, is one type of sensitivity analysis that you could performed  
14 based on residential exposure scenarios. You've taken away my  
15 example. I was going to -- now do I understand correctly that the  
16 DDVP scenario has pretty much gone away? Because that was the one  
17 where it was most obvious that I think the use of the uniform  
18 distribution was a bad idea because you had a case where you have  
19 decay over time which I think you could come up with a physical  
20 explanation for that that would be much more convincing to most of  
21 us. So I won't dwell on that.

1           In terms of criteria for developing what you call parametric  
2 input distributions from available data, I think you need to use an  
3 iterative process that's familiar to the Agency from a lot of other  
4 things, you know, good laboratory practice protocols and SOP and  
5 things like that. Things that ensure studies both are done in  
6 scientifically defensible manner and are statistically defensibly.

7           In the first case, I'm talking about things that have to do with  
8 performing the study using standard scientific methods, using QC  
9 protocols that characterize measurement error and variability. An  
10 example of this would be like chemical measurement use of  
11 appropriate methods, field lab, and calibration blanks, development  
12 and tracking of calibration curves over time, repeat analysis, standard  
13 reference materials and things like that.

14           There's analogous processes for a lot of the survey instruments  
15 that you're -- really, I think, is the nut of the problem is longitudinal  
16 tracking of behaviors, human behaviors, that really most of us  
17 recognize are one of the key uncertainties in this risk assessment,  
18 cumulative risk assessment.

19           Statistically defensible data is not a just question of sample size  
20 but of characterizing the important features of the study design that  
21 ultimately effect the derivation of data useful for this cumulative risk

1 assessment. This means using studies that have large enough sample  
2 sizes to characterize temporal, spatial, and individual variability.

3 It also means that the resulting empirical distribution to data  
4 are good estimators because they're consistent, they're unbiased,  
5 they're robust, and, hopefully, in the end practical.

6 To get back to your question about sensitivity analysis. I think  
7 that what you need to do is along the same lines of what you've done  
8 in other analyses that have been presented at this is you need to block  
9 either by the scenario or the compound and systematically remove  
10 either a chemical or a scenario and see what it does to your outputs.  
11 And that with possibly changing distributions or shapes of  
12 distributions to see what happens are sort of the standard things you  
13 need to do to figure out what's going on and what's driving your  
14 analysis at the upper bounds.

15 In previous Panels, we've recommended, you know, an explicit  
16 analysis where variability and uncertainty are treated as separate  
17 entities and doing a two-stage probabilistic analysis and there are  
18 people here who have more expertise on this than I do on this topic.

19 But in simple terms, the first would state the variability  
20 distributions, i.e., measurement error, while the second would get  
21 away from or characterize the uncertainty distributions. And this

69

1 would allow you to get to what I think is your ultimate goal is being  
2 able to describe the confidence intervals around your final estimate.  
3 It's nice to look at those traces over time, but I think what we all  
4 really want to know is what's your confidence in those estimates at the  
5 end of the day.

6         Apart from that, I have a couple sort of minor points. I agree to  
7 the exclusion of exposures that have been -- registrations that have  
8 been removed. And I do, also, think that the process would be a little  
9 more transparent if you present all the age groups that you've looked  
10 at. A number of people have commented on this. And I just think for  
11 purposes of being complete, folks need to see that.

12         And this whole issue, what I was asking before and couldn't  
13 articulate really well about conditional probabilities and  
14 co-occurrence. You know, whether or not somebody treats 100  
15 percent of their lawn and then 109 percent of their lawn is 50 percent  
16 garden, but 100 percent of the lawn is still treated sort of questions  
17 are things that people are going to have questions about over time  
18 whether or not it's realistic.

19         And I, also, agree that this institutional exposure levels,  
20 schools, day-care centers and all that, has to be looked at in a  
21 systematic way. Although, I agree that there's -- I don't know how

70

1 much those right-to know laws are going to be helpful to you because  
2 a lot of the data that they generate won't necessarily be useful in this  
3 analysis in my experience.

4 DR. ROBERTS: Okay. Thank you, Dr. Adgate. Dr. Freeman,  
5 do you have any comments to add?

6 DR. FREEMAN: Yeah, a few.

7 First, I'd like to compliment Jeff and his colleagues on the work  
8 they have been doing. This is really an amazing undertaking and very,  
9 very challenging. One of the things that I found very interesting was  
10 your figure of residential scenario application and use schedules over  
11 the seasons for each of the regions.

12 I think this is an approach to take because it gets away from the  
13 idea of treating all of the United States as a single entity, which it  
14 isn't. There's enormous diversity in this country in terms of what  
15 you're going to use, when you're going to use it, and why you're going  
16 to be using it.

17 I'm not sure that I'm adding much more to what John has already  
18 said about the uniform distributions. My concern is that if you rely  
19 too heavily on it that it may, in fact, seriously distort the characters of  
20 the distributions that exist. The impact of uniform distribution on an  
21 exposure estimate will be determined to some extent by the

71

1 characteristics of the original distribution and the size of the data that  
2 provided it.

3 With some of the data -- what I do when I have a data set is I go  
4 use my Kolmagorov-Smirnoff test to try to find out what sort of  
5 distribution it has. And if it says that it's not uniform, I won't use  
6 uniform. I'm a very happy to use medians rather than means if it better  
7 characterizes shapes of distributions. And as John was saying,  
8 triangular sometimes is a really good way to go.

9 You asked the question about when it is appropriate to use  
10 empirical data. As a field person, my counter-question would be when  
11 is it not appropriate to use empirical data? I have colleagues who are  
12 model people who say, you don't need any data; all you need is  
13 physical principles and you can do everything.

14 The problem with that is it is the data that is drawn from the  
15 field in terms of what people do, what their exposes are, what the  
16 biomarkers are that actually tells what's happening. So I say use  
17 empirical data whenever you can with great comfort.

18 I would suggest that -- I think in your study you mentioned  
19 something like 11 different variables in which you were using uniforms  
20 distributions. When you're looking at the average individual, I don't  
21 think that's a problem. But if you're look at the 90th or the 99th

72

1 percentile, you may be having extreme effects, creating a high-level  
2 exposure that's not really there.

3 And I think for some of the regional things that seemed to be  
4 the case, that the residential was driving these exposures. And I think  
5 that may be at these high ends because of this multiple magnifications  
6 created by using too many uniform distributions at the same time.

7 And I guess that's what I have.

8 DR. ROBERTS: Thank you, Dr. Freeman. Dr. Hattis, do you  
9 have anything to add?

10 DR. HATTIS: Yeah. I, unfortunately, have a relatively  
11 comment that's going to conflict to some extent with the advice you  
12 got in September 2000. So I'm sorry to be inconsistent. But if you  
13 ask more than one person and they say the same thing, at least one of  
14 them is redundant.

15 First I want to that the EPA staff is to be commended for what  
16 appears to be an initial effort to apply the techniques of distributional  
17 analysis to represent the population variability of residential  
18 non-occupational exposure to pesticides. Unfortunately, the choice of  
19 the uniform distribution for generic application to limited data sets  
20 and summary statistics is very ill-advised.

21 In my experience reviewing probabalistic assessments in the

1 past several years, I found that the uniform distribution is the single  
2 most over used distribution and nearly always significantly distorts  
3 available information about the variability or uncertainty to the  
4 parameters to which it's applied. It is particularly the case where  
5 there are limited directly observed data.

6 Analysts often give the perceived simplicity of the uniform  
7 distribution as an important attraction. Moreover there's often an  
8 impression as stated in the text paragraph introducing this question,  
9 that quote, "it relies on easily established values such as the minimum  
10 and maximum." In fact, it's not to so easy to appropriately establish  
11 true minimum and maximum values from observed ranges from limited  
12 data sets of empirical observations.

13 It's completely incorrect in general to assume that the largest  
14 and smallest values of a group of 10 to 30 data points or fewer  
15 represents the true minimum and maximum values that that parameter  
16 can assume. Moreover, there are few cases where the mechanisms that  
17 cause measurement or estimates of exposure-related parameters to  
18 vary among people to create situations where there is no greater  
19 chance of producing a case near the center of a distribution than at  
20 extreme ends as would be required for the uniform distribution to be  
21 correct.

1           Much more commonly, factors that cause exposures to differ  
2           from one individual to another tend to interact multiplicatively leading,  
3           when this factors are numerous, to expectations of a log normal  
4           distributions.

5           Sometimes where categorical factor of two is likely to have a  
6           strong influence like wearing short-sleeved shirts versus long-sleeved  
7           shirts or short pants versus long pants influencing dermal exposure  
8           from hand spraying on page 14, it's good to create mixtures of log  
9           normal distributions weighted by their expected frequency to represent  
10          the influence of these different known cases.

11          The uniform distribution is appropriate in cases where, one, it's  
12          physically impossible for the parameter to take on values outside the  
13          limits; and, two, there's really no greater likelihood of values close to  
14          the center of the range than at either end. For example, I have no  
15          problem using the uniform distribution to represent the probabilities of  
16          when the meteor is likely to hit, which day of the week for example.  
17          That's not a problem.

18          But my experience is that uniform distribution is often selected  
19          in cases where there's -- anyhow. The other generic difficulty with the  
20          uniform distribution is that it plays into directly into over-confidence  
21          bias which is one of the most reliably established phenomenon in the

75

1 psychological measurements of people's misconceptions of  
2 probabilities.

3 And that same things applies to the triangular. Then my  
4 prejudice would be to say you ought never to assume a defined limit  
5 unless you have a reasonable physical basis to impose that limit.  
6 Otherwise you should tend to expose unlimited distribution.

7 I'll get to ways in which you can put in reasonable limits where  
8 they we must be there in a couple of paragraphs.

9 I want to refer briefly to 1994 paragraph of mine that gives a  
10 series of rules and examples of mechanisms that give rise to different  
11 distributional forms.

12 Experience and the basic idea that variability is often the results  
13 of combined actions of many factors adding multiplicatively indicates  
14 that the log normal form is the most often the best choice for  
15 exposure-related data where there are limited information. Both  
16 normal and log normal distributions have just two parameters, so  
17 they're in fact statistically no more complicated than the uniform  
18 distribution. And there's, you know, relatively straight forward  
19 methods to estimate the parameters of normal and log normal  
20 distributions.

21 The current document doesn't, unfortunately, provide a detailed

1 description of the data underlying it's various choices of uniforms  
2 distribution. Nevertheless, I'd like to make some specific comments  
3 on particular cases to which you've applied this distribution.

4       Page 9, you talk about this distribution of sizes of lawns, and  
5 you've applied this uniform distribution from very small value to  
6 something that's slightly over the mean that was observed in the cited  
7 paper. And I understand why you might want to have the mean of the  
8 distribution you select be slightly smaller than that mean there because  
9 of the presence, as you said, of stuff that takes up area that's not lawn  
10 that isn't included in the calculations that they made.

11       But I would rather you be faithful to the original data and then  
12 have some variable factor for the rest of the thing. As you say,  
13 ranging from 10 to 50 percent, you can easily put that in as a second  
14 variable factor depending upon what your information is that leads you  
15 to believe that it takes up that lawn, those fractions.

16       Pages 11 and 13 give 14 applications of the uniform  
17 distribution. In general, the ends of the ranges provided differ one  
18 from to the other by many fold. Sevenfold, for example, in the case  
19 for inhalation exposure from a hand-pump sprayer to over 1,800-fold  
20 from a hand garden duster. Such large multiplicity ranges are based  
21 presumably on data sets with limited number of observations strongly

77

1 suggest that you better be selecting something like a log normal  
2 skewed distribution.

3 A modified Poisson distribution can also be used in cases for  
4 which there is, in fact, a defined upper limit to a process, for example,  
5 the fraction of pesticide in soil on fingers that's removed by inserting a  
6 child's fingers into his or her mouth. In this case, the fraction clearly  
7 must have an upper limit of one or 100 percent.

8 I handle cases like that by postulating a log normal distribution  
9 of basic transfer rates  $K$  among children and then modeling the  
10 fraction of soil particles or molecules transferred as the fraction that  
11 receive one or more quote "hits" in a Poisson formula. And the  
12 formulas in the thing is very simple.

13 Basically, the fraction absorbed is the 1 minus the fraction of  
14 soil particles that get more than one hits which is 1 minus  $E$  to the  
15 minus  $K$  where  $K$  is log normally distributed. As  $K$  goes to higher  
16 values, then you get toward this natural upper limit.

17 And then I had a comment on of the DDVP that I won't say  
18 because you're going to take that out anyhow.

19 Thank you.

20 DR. ROBERTS: Thank you, Dr. Hattis. We seem to be of some  
21 consensus that too much use of the uniform distribution but some

78

1 differences in advice on what to proceed and what to use elsewhere.

2 Dr. Bull, what do you have to add?

3 DR. BULL: Not much. This is a little outside my area of  
4 expertise, and I bow to the folks that went before me because they're  
5 much more schooled in this area.

6 I did notice one other question I'd just like to ask. Did I  
7 understand in your presentation that the 1 to 2 year old age group is  
8 actually 12 to 35 months?

9 MR. EVANS: Right.

10 DR. BULL: So why don't you call it that? Or is it just -- I have  
11 real simple questions.

12 MR. EVANS: I wish I had a simple answer. But we did go  
13 around and around on this and those are just the little boxes that we  
14 tick in the model. But that's exactly misleading as can be.

15 Dr. Freeman had that question, and I made sure that I found out  
16 how many months that I was. And I'll get that back to the people that  
17 outline it that way.

18 DR. ROBERTS: Let me open it to other members of the Panel  
19 for their viewpoints. Dr. MacDonald and then Dr. Durkin.

20 DR. MACDONALD: Just a few comments on the uniform  
21 distributions. I think I'd take a little more pragmatic approach than

1 Dr. Hattis has suggested. But just have some general principles. If  
2 you got especially a small sample and distribution that really has a  
3 long right tail, then you fit a uniform distribution using the minimum  
4 and maximum, you're going to overestimate the mean and the median.  
5 So that's pulling the values up a bit.

6 But then when you go to generate data, you're precluding  
7 getting any generated values higher than what was observed in the  
8 small sample. And that sort of pulling your answer down in the other  
9 direction, you're going to avoid generating really extreme cases.

10 I'm assuming that your simulations here are all set up in a way  
11 that's fairly easy to tweak because you're expecting a lot of  
12 suggestions for tweaking them. It would seem to be fairly straight  
13 forward just to replace your uniform random number generators by log  
14 normal, gamma, Y-Bole, or for discrete data, negative binomial.

15 I would think that just fitting these by moments and using mean  
16 and variance of your small samples rather than maximum and minimum  
17 and just finding the log normal gamma Y-Bole negative binomial that  
18 matches and trying that and just see how sensitive the results are to  
19 the change. And I think that would be a fairly straight forward  
20 exercise even just to try for a few scenarios.

21 DR. ROBERTS: Thank you, Dr. Durkin.

80

1 DR. DURKIN: Well, Peter, really just made my point.  
2 Although I didn't understand half of words that he used. But I  
3 seriously do want to strongly endorse what Dale has said I think very,  
4 very well.

5 People like to use the uniform because they think it is simple.  
6 They think it's conservative. None of the distributions are all that  
7 difficult. And the log normal is no more difficult than the uniform.  
8 And the uniform, I think, can run the risk -- and I believe I heard  
9 Natalie make this point -- of distorting risk a great deal particularly at  
10 the tails.

11 So while my understanding is not as sophisticated as perhaps  
12 others, I don't think it's a very difficult or complicated issue. So I  
13 would encourage the committee to basically put in the elegant  
14 discussion that Dale has given us.

15 DR. ROBERTS: Okay. Thank you. Dr. MacDonald.

16 DR. MACDONALD: Yeah. Since Dr. Durkin commented on my  
17 terminology, I'd like to make another comment on terminology. And  
18 that's the use of the word "conservative." When we talk -- it's never  
19 clear when you use the word conservative in the documentation here  
20 whether you're meaning conservatively high or conservatively low. If  
21 you want a conservative estimate of exposure, I think you usually

81

1 mean we're overestimating just to protect people.

2 But in the wording of the question here, you're referred to the  
3 conservative estimate at the standard deviation. And I'm just not sure  
4 whether you mean overestimate or underestimate. So I guess I'm  
5 advocating against such general use of the word conservative.

6 DR. ROBERTS: Dr. Heeringa.

7 DR. HEERINGA: I'm trying to go back through my recall on  
8 some initial sessions on residential uses. And I think what may have  
9 occurred here with the use of the uniform distribution is that we  
10 offered an alternative as an SAP to a methodology which was using  
11 constant values for many of these parameters. Essentially, the  
12 suggestion to use uniform or a triangular was in a sense an attempt to  
13 move EPA in this particular simulation off the use of a large number of  
14 constant values, often with very little empirical basis if any empirical  
15 basis, to introduce the sort of any type of uncertainty into the  
16 parameterization of this particular piece of the model.

17 So I think that the suggestion to introduce some distribution to  
18 introduce uncertainty into the estimation. Now, maybe that was a  
19 poor recommend. But it was really in contrast at the time to the use of  
20 fix values and often values without any empirical basis as the basis for  
21 the residential route of exposure.

1 DR. ROBERTS: Okay. Thank you. Any other discussion  
2 among Panel members might help sharpen our recommendation? Dr.  
3 Adgate.

4 DR. ADGATE: Just to say that Steve's right. I think that's  
5 historically accurate.

6 DR. ROBERTS: Okay. Then it seems to be, as I pointed out a  
7 little earlier, the consensus that it would be good maybe to move  
8 beyond the uniform distribution. We have lots of suggestions for how  
9 you might do that. Hopefully. Those might be useful. Do you have  
10 any questions, clarifications back to the Panel about our comments and  
11 recommendations?

12 MR. EVANS: No, I don't.

13 DR. ROBERTS: In that case, let's go ahead and take a break  
14 now. I'll reconvene in 15 minutes, and we'll take the second question.

15 [Break.]

16 DR. ROBERTS: Let's go ahead and begin. Before we tackle  
17 Question 2, I believe Ms. Mulkey wanted to make a comment.

18 MS. MULKEY: Yes. I think it would be a good idea to clarify  
19 the regulatory information on DDVP pest strips, as I understand it,  
20 perhaps a misimpression we gave you. We wanted to that analysis  
21 will, also, have to consider a different scenario.

1           But, in fact, the regulatory status of the pest strips is that the  
2 registrant -- well, first of all, I should say that DDVP is one of a  
3 handful of remaining organophosphates where we have not completed  
4 the risk assessment and the risk management process for the chemical.  
5 So it is still one where are actively working through the issues specific  
6 to the individual chemical.

7           The registrant of that product has asked us on a voluntary basis  
8 to remove from their labeling the authorization or the labeling for use  
9 of the pest strip in primary living areas such as bedrooms, living  
10 rooms, kitchens, any primary living areas as I understand it. But the  
11 product would continue to be marketed even during this period for  
12 areas such as closets, basements, attics, garages, perhaps. And I'm  
13 speaking without absolute precision. I don't have the labeling with  
14 me.

15           I believe this is consistent with the regulatory status of the  
16 product in California. But as of now, the registrant has not  
17 voluntarily amended its license to prohibit those uses. They have  
18 instead voluntarily changed their marketing, that is, their labeling for  
19 that period.

20           So unless and until we complete our regulatory conclusions  
21 about the product, I think, and in light of the limitations or the scope

84

1 of the voluntary actions by the registrant, we should not leave the  
2 impression that the DDVP pest strips are quote "canceled."

3 And I wanted to say that early enough that if that caused you to  
4 be more interested, any of you, in talking about that part of the risk  
5 assessment, it does not appear to be moot or irrelevant, those parts of  
6 the risk assessment.

7 DR. ROBERTS: Thank you for that clarification.

8 Let's go ahead and take Question 2. Could you pose that one to  
9 the Panel. You did, by the way, a great job on the first one.

10 MR. EVANS: The use of calendar based models also allows  
11 exposure assessors to consider exposure from a variety of sources  
12 from the same or from different chemicals. Longitudinal survey data  
13 such as the national Human Activity Pattern Survey (NHAPS) are  
14 available for consideration by HED for use in future assessments. In  
15 addition, from a practical standpoint, the use of such survey data  
16 ensures combinations of exposure do not come from unrealistic  
17 random combinations that current models may produce (e.g., activities  
18 adding up more than 24 hours in a day).

19 The use of calendar-based models provides an opportunity to  
20 explore the potential for the co-occurrence of multiple sources of  
21 exposures from residential pathways. In the cumulative assessment,

1 OPP used summary statistics from sources such as the Exposure  
2 Factors Handbook (EFH) regarding the time spent indoors, time spent  
3 on lawns, and time spent at other outdoor locations. In the  
4 preliminary assessment, we assumed these activities were  
5 stochastically independent.

6 OPP is currently evaluating data in the EFH such as data from  
7 the NHAPS to determine if it can directly incorporate (i.e.,  
8 empirically) information on an individual's activity patterns over a full  
9 day from this database to account for the likelihood and duration that  
10 an individual might be exposed to a pesticide through various  
11 activities over the course of a day.

12 Please comment on whether and how OPP might directly  
13 incorporate NHAPS or similar time use data into the software to better  
14 account for variation in activities across individuals?

15 DR. ROBERTS: Thank you. Dr. Freeman, any suggestions in  
16 that regard?

17 DR. FREEMAN: Basically, I was trying to think about that.  
18 And what I said was, Gee, what you really need is a statistician. But,  
19 in fact, I think incorporating NHAPS might be done similarly to the  
20 way the dietary data was incorporated for that model.

21 I love NHAPS. I think it's a great data set, but there are

1 problems. One of them is that while it is a very rich data set, it is  
2 about half the size of the CSFII. It only has about 10,000 cases for  
3 the United States. And if you are then breaking it down in terms of  
4 children of different age groups, you're beginning to get into small  
5 numbers again. Small is relative. We're talking hundreds across the  
6 United States.

7       There is, also, the problem that there are several versions of the  
8 NHAPS questionnaire that were used. And trying to integrate results  
9 of them, I'm not sure how you do it. That's going to take somebody  
10 who really knows how to work with those data sets.

11       One of things that's really great about NHAPS, which would be  
12 very useful for you, is that if you look at the data as a whole, you can  
13 see both regional and seasonal differences in activities. Everything  
14 from ventilation, whether you have your windows open or not. In the  
15 winter, it's very different in Minnesota than it is in Florida. This is  
16 very useful in you're looking at infiltration from outdoors or things  
17 like that.

18       If you go back to the children, if you then break it down either  
19 by region or season, you're getting into small numbers. And if you  
20 break it down by both, then you're really into small numbers. You're  
21 getting to where we are with the hand-to-mouth stuff, you know, 10 to

87

1 30 in a group. And that's very, very frustrating.

2 But at the same time, there may be differences that you want to  
3 pick up when you're doing this regional analysis. And I'm not sure  
4 how you're going to want to play the game. Whether you're going to  
5 want to use, for instance, all children between the ages of 12 and 35  
6 months for the nation as representative of kids all over the place so  
7 you can look at seasonal differences or whether you want to break it  
8 down by regions or forget the seasons. It's going to be a little bit of a  
9 challenge there.

10 One of the other things that you talk about, ask questions about,  
11 is whether or not activities are independent. Many activities that  
12 people engage in, not only activities but where they engage in them,  
13 are not independent either within a day or across days.

14 For school age children, children of people who work, and for  
15 adults who work, both daily and weekly activities time allocated to  
16 them when they are done and where they are done are driven by the  
17 occupation or for the school-age children by being a school-age child.

18 You have to keep that in mind when you're going to be drawing  
19 from this wonderful rich data set that some of the things for  
20 individuals are not independent.

21 I guess that's all I have to say.

88

1 DR. ROBERTS: Okay. Thank you, Dr. Freeman. Dr. Adgate,  
2 would you like to add something.

3 DR. ADGATE: I don't have a whole lot to add to that. I think I  
4 said pretty much what I was going to say in response to the first  
5 question.

6 The one additional thought that I have is that -- and I'm not a  
7 statistician and they probably ought to be consulted on this -- there  
8 are techniques that exist for estimating longitudinal patterns and  
9 distributions from what is essentially cross-sectional data. And I think  
10 that's a general problem that you have with a number of your analyses.  
11 And it might behoove you to put some resources into that general  
12 problem in seeing how you can apply it where you need to as a tool in  
13 this analysis.

14 DR. ROBERTS: Thank you, Dr. Adgate. Dr. Hattis.

15 DR. HATTIS: Yeah. I think, generally, the idea of  
16 incorporating the activity pattern data over sequence days is a good  
17 idea. And the likelihood is that these things are going to be associated  
18 with weights that you can use to adjust your population weights of  
19 each individual that was studied in the survey.

20 I would say that, as we go forward, in general, the approach  
21 here should not be a rolling average but a very simple compartmental

1 model in which the cholinesterase inhibition tends to decay at some  
2 rate that can be inferred from one model of the approach to steady  
3 state observable in the animal experiments.

4 And, two, a human-animal adjustment factor to take into  
5 account that we big animals tend to metabolize and eliminate things at  
6 a slower rate. And the center of that distribution is usually  
7 approximately given by a animal body weight to human body weight to  
8 the one-quarter power-type formula as Lorenz can testify to.

9 I basically got -- as to the uncertainty of that translation, I've  
10 got some recent work that sort of gives the observed spread of  
11 animal-human conversion factors, in this case rat-human conversion  
12 factors, based upon the old Frederick data sets and several other sets  
13 that have been compiled by Paul Price.

14 To make a long story short, for the 18 rat-human projections  
15 that were available, sort of the geometric mean departure of the human  
16 potency from the observed animal toxic potency for these anticancer  
17 agents was about .89 with 95th percentile of about, you know, 4.3.

18 Anyhow, there's some real data that can be used to get the  
19 uncertainty and what, at least, a starting animal-human projection  
20 factor for the reduced metabolism rate is that can be used for that kind  
21 of modeling. And I cite a reference here.

1           But basically the 7-day window or a 21-day window is possible.  
2           It's almost as easy to model the co-expected brain cholinesterase  
3           inhibition itself with the adjustment that you should expect the humans  
4           to eliminate the inhibition at a lesser rate than the rats do.

5           Whether that's something that you want to attempt for June or  
6           on some longer-term basis, it's up to you.

7           DR. ROBERTS: Dr. Reed.

8           DR. REED: I don't have a whole lot to add into what's been  
9           said.

10          I'm really excited about data becoming available. I'm curious  
11          about and I'm not a statistician and I'm not ready to make some  
12          recommendation or anything. But I'm curious about how the different  
13          data bases could be used together in separate sets or how that choice  
14          would be. I'm hoping that someone might be able to make some  
15          comment about this issue. I think it's very important.

16          The other one is sort of not directly about this question, but I  
17          think it's an important point. It might be a good place to bring it up.  
18          It's that the importance of doing a mass balance whether it's been time  
19          or location or anything. I think in one of the previous meetings we  
20          brought up an issue or the concern about such a situation where, if a  
21          certain proportion of the ratio has been taken up from the same

91

1 location area or contact surface, then it should be that it's no longer  
2 available for the next time series exposure.

3 So that I would like to see a more clear coverage on that issue.

4 DR. ROBERTS: Dr. Durkin.

5 DR. DURKIN: Since I'm kind of at the anchor position here for  
6 exposure assessment, I do want encourage, of course, the use of  
7 calendar-based models in response to the question that you proposed  
8 to us to the extent that we can demonstrate that they lead to plausible  
9 results. But there are a few other odds and ends with the exposure  
10 assessment that I would like to bring up briefly.

11 Two of those relates to comments that we heard from the  
12 public; one being the transparency, the ability to drill down by  
13 chemical. I was thrilled to see the graphics from the drinking water  
14 folks who were showing us over time the different individual  
15 chemicals. I haven't seen that in food. I think that sort of thing is  
16 very important, and I want to encourage that kind of transparency.

17 The other minor footnote that I will pass on is that, on the issue  
18 of inhalation exposures, I think you have addressed extremely well,  
19 perhaps not in the document that we are dealing with here but in a  
20 document that you referenced. I went and got ahold of it; it's your  
21 document on I think it's called "Residential Exposures," rather large

1 and it's on your web site. And in general, except for things like  
2 DDVP, the inhalation exposure, I think, it's relatively well known and  
3 documented is going to be extraordinarily small compared to the  
4 dermal and oral exposures.

5 Two other points. One is I am a little concerned that my lap top  
6 always goes to sleep when I look at it. Okay, there we go.

7 The one sort of serious concern that I have about your exposure  
8 assessment is the failure to address populations that live adjacent to  
9 sites where there might be a lot of agricultural use. To me,  
10 conceptually, this is something like the sorts of exposures that you did  
11 address with sprays for public health which I think was very  
12 appropriate.

13 But there is a subpopulation, and I don't know how big it is.  
14 But they do live adjacent, right up next to things like cotton fields,  
15 tobacco fields where there are a lot of chemicals put out over the  
16 course of a growing season. And these people do have gardens. They  
17 have lawns. The extent to which you want to look upon them as maybe  
18 a typical subgroup; I can't really answer that. I don't know. But I just  
19 bring it to you for your consideration.

20 The last point that I'll address again, just briefly, relates to how  
21 you do your exposure assessment and then start to segue into risk

1 characterization. And this is really a follow-up from a question that  
2 Dick Bull had.

3         What you have always done with the pesticides has been to  
4 combines different routes of exposure by taking the let's call it a  
5 "point of departure" for the route-specific points of departure. So you  
6 take an oral study, an inhalation study, and a dermal study; and then  
7 you take ratios to the exposures by the same routes. So you're not  
8 really doing route-to-route extrapolation; and that's fine.

9         I'm not critical of it. But I do think the document might benefit  
10 from at least addressing why you don't take the other approach, that I  
11 think Dick is comfortable with and I am as well, and, in fact, it is one  
12 that I tend to use, where you take the multi-route exposures and do  
13 your best to convert it to an equivalent oral dose and then you use the  
14 oral tox data as your point of departure. The nice thing I can say  
15 about that approach, and you ran into this with your analysis, is that,  
16 in general, the oral studies are more abundant and they tend to be  
17 better. A lot of the dermal and inhalation studies, first of all, there's  
18 fewer of those and they often do not have the same quality. And this  
19 is particularly true had you look at the longer term effects.

20         So I'm not trying to proselytize here to get you guys to convert  
21 in any way. But I do think it is something worth talking about in the

94

1 document because I do think it makes a difference in your ability to  
2 characterize risk.

3 And I would, also, note that taking that route-conversion  
4 approach is going to end up very consistent with where I see you  
5 going, and we'll talk about this at the very end of the day or tomorrow,  
6 where I see you going with PPBK models as you have discussed in  
7 your future dates.

8 So that's all I have. Thank you.

9 DR. ROBERTS: Thank you. As Chair, I appreciate the interest  
10 in panel members in getting in comments before we move away from  
11 exposure into risk characterization, that it may be not exactly to the  
12 questions being posed.

13 Let me ask the Panel members, though, as we go through the  
14 questions, let's go ahead and focus our comments and feedback on the  
15 specific questions. And if we will sort of maintain our discipline in  
16 that regard, I will promise the Panel the opportunity this afternoon or  
17 at the end of the session to offer whatever comments they might have  
18 had that just didn't fit in with the questions or they didn't get the  
19 opportunity to raise earlier. And that would apply to any of the  
20 aspects of the cumulative risk assessment, hazard and dose response  
21 exposure, risk characterization and so forth.

1           With having said that, are there any comments from other  
2 members of the Panel as it specifically relates to the question posed to  
3 us here by the Agency?

4           Let me ask the Agency, would you like some clarification on our  
5 response to this question, or is it pretty clear?

6           MR. EVANS: It's pretty clear.

7           DR. ROBERTS: Okay. Great. Then if they're no other  
8 comments on this question. Let us proceed to risk characterization.

9           If the Panel will note, and the audience as well, that we are well  
10 ahead of schedule. I believe that it is possible for us to complete our  
11 discussion of these questions this afternoon. Having said that, I want  
12 to assure the members of the Panel that they will have every  
13 opportunity discuss the remaining issues as fully as necessary as well  
14 as having the opportunity to make these other comments as I indicated  
15 just a moment ago.

16           To alert the audience, I think we're going to finish the program  
17 today. We'll stay as long as we need to do that, so we might run a  
18 little bit long today. Barring some disaster, and if that takes place, I'll  
19 ask the Panel to meet tomorrow morning. The session will be closed  
20 today. Meet tomorrow morning at 8:30 to discuss report writing and  
21 coordination.

96

1 DR. ROBERTS: Dr. Doyle, welcome.

2 DR. DOYLE: Thank you very much. Dr. Miller is kicking off  
3 the presentation. He's coming in just now.

4 DR. ROBERTS: Okay. Here he comes now.

5 DR. ROBERTS: Mr. Miller, are you ready to go with risk  
6 characterization?

7 MR. MILLER: Yes.

8 DR. ROBERTS: Great.

9 MR. MILLER: If I can just have the first slide and then the next  
10 one.

11 Okay. What I'll do first is just kind of go through the outline of  
12 the presentation. Before I go through the outline, I'll just kind of  
13 quickly go through kind of what you've before in the sessions here.

14 On Tuesday you heard from Anna Lowit and Woody Setzer a  
15 little bit about BMD10s, that those were 21-day steady state  
16 equilibrium cholinesterase inhibitions based on that time period.

17 Yesterday, we discussed with you some of the mechanics of the  
18 analysis options within DEEM and Calendex. Two options were single  
19 consecutive day, and the second option was the rolling time frame.

20 Today this session is concerned with comparing the time frames  
21 of exposure, for example, 1, 7, 14, 21 or 28 days which are available

1 within DEEM Calendex with a time frame of toxicity 21-day BMD10  
2 talked to you before on Tuesday by Anna and Woody.

3 Just in this outline here, this slide here, we're going to be  
4 talking first just a summary of preliminary results and findings. A  
5 single slide on that. Then we'll be talking about introduction to key  
6 principles for conducting risk characterization. I'll talk a little bit  
7 about the hazard and exposure aspects.

8 I'll talk about what we did in the preliminary cumulative risk  
9 characterization assessment. I'll remind you about the time frame  
10 considerations and some of the specific comparisons that need to be  
11 done between toxicity and exposure.

12 After that, what we'll do is some example exposure scenarios,  
13 and Beth Doyle will be discussing this kind of in a more interactive  
14 session with you with overheads. And then finally we go through the  
15 questions for the SAP.

16 Just as kind of a summary of the preliminary results and  
17 findings. In general, we found consistent exposure at risk patterns  
18 across regions. The major contributors to risk for indoor residential  
19 exposures are uses of DDVP. Exposure through food is considered to  
20 be national and does not vary by region. We're performing additional  
21 analyses on these results, and Bill Smith went through these with you

98

1 yesterday.

2           And then, finally, drinking water and outdoor lawn and garden  
3 uses do not appear to be significant contributors to risk.

4           Some key risk principles for conducting a cumulative risk  
5 assessment. One key consideration is the time frame of toxic effect.  
6 For example, what is the time to the peak effect and what is the time  
7 to recovery.

8           With respect to time frame of exposure, some key  
9 considerations include how often does exposure occur, at what levels  
10 do exposure occur, and then what is the exposure duration. And then,  
11 finally, what some consider to be the crux of the issue would be how  
12 are exposure and toxicity compared; to what degree to the time frames  
13 need to match between exposure and toxicity.

14           In the September 2001 SAP meeting this was considered of how  
15 to compare the time component of toxicity endpoints with the time  
16 component of exposure. You said the cumulative risk assessment  
17 should ideally compare toxicity endpoints and exposure durations of  
18 the same time frame and, also, that, to the extent possible, comparison  
19 should take into account the pattern of human exposure.

20           With respect to -- I'll give you a reminder of some of the hazard  
21 aspects that you'd heard about from Drs. Lowit and Setzer. The

1 BMD10 is based on steady state or equilibrium cholinesterase data.  
2 That's the point at which continued exposure at the same dose level  
3 does not result in further reduction in cholinesterase activity.

4 The RPFs and PODs are based on studies of 21 days or longer of  
5 continued dosing of naive animals, that is, animals not exposed to OPs  
6 before the initial dosing period. This represents 21-day steady state or  
7 equilibrium conditions for cholinesterase inhibition and believes to be  
8 a more stable measure of relative potency factors and points of  
9 departure.

10 And then finally following the insult, recovery of cholinesterase  
11 inhibition that may requires days to weeks.

12 With respect to the exposure aspects, human exposure patterns  
13 to multiple OP pesticides may be single day, for example, spike or  
14 short-term exposures through food, drinking water, and residential  
15 uses, superimposed imposed upon more or less continuous exposures  
16 through food. By monitoring data from NHANES, for example,  
17 suggests that a sizeable portion of the population have OP metabolites  
18 in their urine.

19 It should be remembered, also, that most animal data available  
20 to OPP are developed using laboratory animals that were naive in their  
21 exposures to OP; that is, again, they were not exposed previously to

100

1 OP pesticides.

2 Continuous exposures through food might resemble the  
3 multi-day dosing used in determining the BMD10.

4 The preliminary cumulative risk assessment used the BMD10  
5 which reflects continual dosing for a sufficient period to produce  
6 equilibrium response. More specifically, the BMD10 used in the  
7 preliminary cumulative risk assessment is based on a multi-day animal  
8 studies, dosing studies, and reflects that multi-day dose required to  
9 achieve a steady state 10-percent inhibition of cholinesterase.

10 In the PCRA, OPP developed a distribution of single  
11 consecutive day exposures, again, not rolling time frame, and  
12 compared this to a steady state or equilibrium multi-day BMD10.  
13 What we indicated we would do would be consider the patterns of  
14 exposures, looking for periods of sustained elevated exposure over a  
15 period of time. And we indicated to you, again, yesterday that we  
16 recognize that such sustained elevated exposures at high percentiles  
17 are unlikely to reflect the same single individual.

18 DEEM(FCID)/Calendex also permits the rolling time frame  
19 approach. This measure exposure to the same individual. They are  
20 tracked. The same individual is tracked over the time frame of interest  
21 and averaged for that individual over that time frame. The SAP

101

1 considered this issue in yesterday's session of this meeting.

2       While this rolling time frame approach may allow for a better  
3 match between selected exposure time frames, for example, seven days  
4 or longer and the hazard endpoint, BMD10, OPP is concerned that this  
5 may not adequately permit estimates of risk associated with shorter  
6 duration exposures, for example, a single day spike or short-term  
7 exposures.

8       While an advantage of the rolling time frame approach is that it  
9 better simulates continual non-naive exposures and allows us to better  
10 match the time frame associated with the toxicological data, results of  
11 this averaging process may obscure one-day spike or elevated time  
12 frame short-term exposures.

13       BMD10 associated with a 21-day steady state response is  
14 appropriate for 21 days or more. If an acute, for example, a one-day  
15 or short-term, less than 21 day, exposures, if those are of concern,  
16 how might OPP evaluate or compare such exposures with toxicity data  
17 that is based on a multi-day BMD10. In other words, how does one  
18 estimate the effect of different exposure patterns on risk given those  
19 two pieces of information?

20       Some information is available with respect to how multi-day  
21 BMD10s compare to one day NOAEL, no observed adverse effects

1 levels. This information was provided to the Panel in a supplemental  
2 submission in January 25, I believe. A rough comparison of the  
3 BMD10s with a no observed adverse effect levels based on the  
4 cholinesterase estimates data from single-dose studies reveals a good  
5 similarity of values based. Keep in mind, though, that it's based on a  
6 limited data set and there are some exceptions to that.

7 This next session it would be by Beth Doyle, in terms it would  
8 be an interactive session with transparency acetates. I don't know if  
9 you'd like to ask clarifying questions or hold off until after lunch.

10 DR. ROBERTS: Let me go ahead and ask the Panel if they've  
11 got any clarifying questions on what you've presented so far. I don't  
12 see any. So let's go ahead then.

13 DR. DOYLE: As we discussed before, is it better to do this  
14 right before the question or after lunch? What would be your  
15 preference, Dr. Roberts?

16 DR. ROBERTS: Now. I'm seeing some people say they want to  
17 go ahead and talk about it now.

18 DR. DOYLE: One of our concerns is that we have a very  
19 thorough discussion of the matching of the time frame for the exposure  
20 with the appropriate hazard endpoint. And we have tried to frame here  
21 for you, in a very loose way, a number of things that we have

103

1 considered as issues. We wanted to impress upon you the variety of  
2 types of issues that we have to deal with in this assessment and some  
3 of the complexities that we see. And we'd like to hear other  
4 complexities you think we've misses and also suggestions for how we  
5 might best deal with this.

6 So I'd like to graph out for you some of the issues to frame-up  
7 the discussion. One of the concerns we have is that we have a variety  
8 of different potential exposure patterns. If you bear with me, let me  
9 draw the first. Unfortunately, our markers are dead.

10 But the first exposure pattern with which we have concern is  
11 one in which there is a very low background and there is a spike above  
12 a very low background.

13 This is about a 40, roughly 42-, 45-day time frame. We have a  
14 potential that we have an exposure that looks something like this.  
15 Okay. In this case you have a very low background exposure,  
16 essentially, no exposure at all. And that will run along for a series of  
17 days and then very abruptly a peak of exposure occurs, followed by a  
18 rapid decline and then another very low exposure.

19 Now, you might argue in a case like, if this is our 21-day  
20 BMD10, that is not an appropriate endpoint for consideration there  
21 because, in fact, you have essentially a true acute exposure. It might

1 be argued that this would be more appropriately reflected by an acute  
2 NOAEL of some sort.

3       However, if the acute NOAEL is up here, you can see it makes  
4 quite a difference. Now, that depends to some extent, though, on how  
5 you express your exposure because there's been a discussion of rolling  
6 time frame. So we're further faced with the issue that if we do a 7-day  
7 rolling time frame, we get something like this. And that sort of shifts  
8 our type of concern that we're dealing with quite a bit because you  
9 maximum exposure has fallen tremendously. But you have a very wide  
10 period of exposure to consider.

11       So by looking at the manner in which we do the calculation of  
12 exposure, we have changed the question, and perhaps artificially; but  
13 we certainly have changed the nature of the question. And you could  
14 continue to widen and lower that peak based by using a longer  
15 averaging time.

16       Now, we have an alternative possibility which we may be  
17 dealing with. We don't know. It looks something like this. This is a  
18 higher background level. If you recall, we had a BMD10 that looks  
19 something like this. And in this case, your background -- okay. In  
20 this case we have a BMD10, which is very close to our background  
21 level, so we're running at an exposed individual, they're already

105

1 inhibited. Suddenly they incur this peak exposure.

2       Now this is a little bit of a different situation that you have with  
3 our tox data for our acute exposure assessments. You don't have a  
4 naive, if you will, person being expose to a sudden pulse. You have a  
5 person who already has a substantial potential degree of inhibition.  
6 It's not unsafe yet at background. But when you hit this peak, you're  
7 rising not from zero anymore but from previous exposure.

8       So, again, then it becomes a little more problematic about what  
9 would be the appropriate toxicity scenario to use for comparison. And  
10 if we do a rolling 7 day, then you get a different picture much like  
11 before. Looks something like this. And, again, I'm sorry for the  
12 drawing. I'm very poor at this. You get something like this, which  
13 spreads out the exposure. Well, it comes down. But it does spread  
14 out the exposure and, again, widen that peak substantially.

15       Again, the question, I think, is different now, what the  
16 appropriate toxicity comparison is, because you're not starting at zero.  
17 You have a substantially exposed population that's now receiving an  
18 insult. So that's a different sort of issue.

19       And then we come into the situation where we have a series of  
20 spikes. And regardless of what your background is, it raises another  
21 question for us. and we have to deal with this one as well. And, say,

1 for instance, it's going like this and you have a spike; and then maybe a  
2 week later or a few days later you get another spike and so forth.

3 Now, this is a daily series. And, again, here's our BMD10; and  
4 here's our acute. Well, certainly there would be a certain simplicity in  
5 being able to say these are three acute values. And that would be very  
6 easy to do.

7 Except that if you look at a rolling average, you get something  
8 that starts to ooze together. You start to get something that sort of  
9 like this. And then it goes down after. But, in fact, your exposure  
10 with decline included, may never truly go back down to even your  
11 background. You may have a sustained elevation. And it's a little less  
12 apparent.

13 Again, these are certainly three independent exposures now  
14 because they're too close together. And we haven't even gotten into  
15 discussing recovery at this point. We're just looking at exposure.

16 And last but not least is what we're afraid we probably have,  
17 and some of our scenarios suggest that we do have, is a mixed  
18 situation where you're going along at background and all of a sudden  
19 you have an elevation of some sort. Maybe you've been working in  
20 your lawn that day. And then after a while it goes back. And all of a  
21 sudden you get a peak from some other use and another peak and so

107

1 forth.

2 Well, you can argue very effectively, I think, that for this  
3 portion in here, that BMD10 is probably appropriate for this section if,  
4 in fact, this is an individual exposure and you're seeing the sustained  
5 elevation. That certainly is a subchronic exposure and that would  
6 make sense.

7 But if you go to each separate peak, it's less clear that those are  
8 actually acute exposures because depending on how you look at your  
9 averaging time for presentation, you're actually doing something akin  
10 to this. And then it goes back up here a little more. I'm sorry.

11 At any rate, you have something then that remains elevated for a  
12 substantial period of time. And I think that we have these issues with  
13 regard to exposure scenarios. But we have, also, issues with regard  
14 to, as I said before, recovery of cholinesterase inhibition. Dave  
15 mention that in his presentation. You could argue a person never  
16 recovers in this scenario between exposures.

17 The same is true here. And then you have to allow for the  
18 distinction of what your starting point is. What is your baseline  
19 condition of your exposed individual? Are they truly what we're  
20 referring to as naive, that is, never previously exposed. Or are they  
21 previously exposed that are now incurring a separate additional insult.

1           So we just wanted to frame this up a little that these are the  
2           variety of types of issues that we'd like to see you think about. We  
3           have no single answer, necessarily, that's the right one that we're  
4           looking for. We would be happy to see a variety. We are open to any  
5           suggestions. And I'd like to thank you for your comments in advance.

6           DR. ROBERTS: Thank you, Dr. Doyle. Are there any other  
7           aspects of the presentation? Let me, then, open it to the panel for  
8           questions of clarification. Let's try and avoid getting into the  
9           comments, but certainly clarifications on these issues are fair game.  
10          Dr. Bull and then Dr. Conolly.

11          DR. BULL: Mine was part of the comments.

12          DR. ROBERTS: Okay. Dr. Conolly.

13          DR. CONOLLY: Yeah. I just wanted to be absolutely clear. I  
14          think it was pretty clear that the graphs you were drawing were graphs  
15          of exposure. And so really the question you're asking is what's the  
16          linkage, what's the appropriate linkage, between the exposure and  
17          cholinesterase level.

18          DR. DOYLE: That's correct. And, again, the averaging time  
19          for the exposure will affect that. All of those things combine to give  
20          us a very complex question.

21          DR. CONOLLY: Right. Thank you.

1 DR. ROBERTS: Any other questions from members of the  
2 Panel? If not, I believe we have some public commentators that are  
3 interested in making a presentation. Mr. Jack Zabik from Dow  
4 AgroSciences. Is Mr. Zabik here?

5 MR. MCCALLISTER: Jack Zabik's not here. I'm taking his  
6 place.

7 DR. ROBERTS: Okay. Welcome. And could you introduce  
8 yourself for the Panel, please.

9 MR. MCCALLISTER: My name is Ray McCallister. I'm with  
10 the Croplife America here representing the FQPA Implementation  
11 Working Group.

12 Comments are fairly limited, and they're not going to address all  
13 the issues that EPA has just raised. But I wanted to say that the IWG  
14 strongly supports the multi-day rolling exposure calculation to match  
15 the toxic endpoints which is also based on a 21-day or longer exposure  
16 test animals. In the risk assessment the exposure and toxicology  
17 scenarios must match as the panel has previously advised the panel and  
18 repeated during these sessions.

19 The Agency has raised questions in sessions yesterday about the  
20 use of the available food consumption data to approximate a moving  
21 dietary exposure average. Some of those questions raised would tend

110

1 to make the risk calculation more conservative; some less  
2 conservative. And Panel members raised additional issues that need to  
3 be taken into account.

4 For example, I feel that the list of foods and commodities that  
5 would influence the leftover issue, that is, what foods might be more  
6 likely to be consumed on subsequent days, is probably fairly limited  
7 and can be fairly easily defined.

8 EPA has in hand now data from industry and from USDA that  
9 directly address the homogeneity or variability of residues within a bag  
10 of apples or oranges or potatoes to determine how variable those  
11 residues would be, how likely the residues of fruit consumed from that  
12 bag tomorrow are going to be similar to those consumed today.

13 The EPA can and should call on the expertise of USDA's Food  
14 Surveys Research Group in addressing these issues of estimating  
15 longitudinal dietary consumption. These are the folks that conduct the  
16 CSFII study. They may not have solved all the problems that were  
17 raised by EPA and by the Panel members, but they have considered  
18 them analytically for years and will have valuable insights to offer.

19 The CARES software model is designed to specifically address  
20 some of the issues raised by Panel members. For example, it assembles  
21 a pool of demographically similar individuals for use in approximating

111

1 a rolling average of dietary consumption.

2 The issue of the spikes and exposure rates today must be  
3 addressed by combining consideration acute tox values as well as the  
4 chronic tox values.

5 Finally, the IWG has benefited considerably by the EPA's  
6 presentations and the SAP discussions of the cumulative risk  
7 assessment issues. We will be providing detailed comments to the  
8 Agency during the public comment period on the new issues that have  
9 been raised by during these sessions.

10 DR. ROBERTS: Thank you. Are there any questions?  
11 Clarification? Thank you very much for your comments.

12 Let me see. We one other individual that has indicated an  
13 interest in addressing the Panel. Dr. Christine Chasen if I pronounced  
14 that correctly.

15 Okay. Could you please identify yourself for the record.

16 DR. CHASEN: You were close. It's Chris Chasen, and I'm with  
17 the Lifeline group. And we've had the pleasure of presenting Lifeline  
18 to this Panel before. We will be presenting some written comments to  
19 you. But I just wanted to point out a couple of issues for your  
20 consideration.

21 There's been intermittently discussion about the dilemma that

1 we always face when we're trying to fit cross-sectional data into what  
2 basically are longitudinal questions. And there are two components to  
3 that. I just wanted to point this out.

4 One, of course, is that we've all saluted the problem that there  
5 are not adequate longitudinal data sets that are in any of these and so  
6 about it. So we have to do the best we can with the cross-sectional for  
7 the moment. I was very pleased to hear the Panel endorse the idea that  
8 you can, however, use cross-sectional data if you take a look at some  
9 of the relationships that are referred from other data bases. And so  
10 there is still a lot of improvement that we can all make in how we use  
11 the cross-sectional.

12 However, I didn't hear very much conversation about how the  
13 models use the cross-sectional data. And this is really important.  
14 Because even with completely cross-sectional information, how the  
15 models handle it is really going to be important. I'll give you just one  
16 of this; but there are many, many, many places in these models where  
17 this becomes important.

18 One example would be that you got to keep the individual in the  
19 same house from Day 1 to Day 2 to Day 3 to Day 4 until they move.  
20 And that has to be an abrupt difference. So when you talk about  
21 modeling a person across some X amount of time, it's not -- the model,

113

1 in fact, can take the concept data that we have about mobility  
2 characteristics in the United States and whatever, and at least hold  
3 that person in a house that is consistent from day to day.

4 The same would be true. There are socioeconomics. You can't  
5 get rich one and go poor the next one, although that seems to be  
6 happening. We have to adjust the model accordingly. And, also, hold  
7 these people in an urban or rural setting so they don't bounce back  
8 from Iowa to New York City. There is, in fact, a significant use of  
9 pesticides in urban situations, and we're considering residential  
10 treatments here.

11 A second. I'm just going to go briefly through a couple of these  
12 points but we'll be elaborating on that.

13 Another one is I think we need to take a look at seasonality just  
14 a bit more because I think we may be overlooking one important thing.  
15 I will concur that in the United States there is not much difference in  
16 the intake of foods from one season to another. That seems to be even  
17 true with water. And that may be a function of air conditioning or  
18 something. But we do have -- now there are exceptions to that, of  
19 course, in our food supply. And I think most those are obvious, and  
20 we would know that.

21 However, there is a difference seasonally from residues, on the

1 residues on the foods. So I don't care whether it's an apple or an  
2 orange or orange juice, whatever, the source of that food changes in  
3 the United States seasonally. And even though it's nationally  
4 distributed, the source of the national distribution changes radically.

5 And obviously, if you're changing the source, you're changing  
6 the pest pressures; and obviously, then, you're changing the patterns  
7 of usage. So it's not surprising that if you superimpose on the model  
8 one usage profile in the calendar base, you're going to end up with an  
9 answer that says there's not much difference from season to season.  
10 But, in fact, you need to be able to take a look at the source.

11 If you don't take a look at the source, you also can't account for  
12 import versus export situations. Now we may know an awful lot about  
13 usage profiles in the United States. But how much do you know about  
14 the other usage profiles from where our increasing percentage of foods  
15 are coming.

16 I know that the PDP data set does look at imports, but there are  
17 other ways where we can account for the what we don't know of  
18 pesticide usage from the food imports. And that wasn't discussed.

19 Another thing that was not discussed was how the models use  
20 the water intakes, the consumptions of water, particularly for kids.  
21 We're going to put in just some basic information if you want about

115

1 the water intake distributions in CSFII '94, '96, '98 for the Panel from  
2 kids in different age groups, including infants. When we were working  
3 with Lifeline, we went through exactly these issues. And we'll share  
4 the background information that we have on that and the subsets of  
5 information out of those data sets.

6 Lastly, as you heard, Lifeline will be running this. I just wanted  
7 to emphasize that the results of that effort will yield three things. We  
8 will certainly have a final report with new manuals. Secondly, we will  
9 have a disk with the inputs and the results from the analysis. And  
10 thirdly, a free copy to anyone who wants it of the complete version of  
11 Lifeline that was used to run those risk assessments. So you'll be able  
12 to put the data in, play with it however you want, take a look at the  
13 drivers or whatever else is of interest.

14 As part of this, you know that Lifeline has shown you those  
15 situations where it looks like there's less exposure to certain age  
16 groups when in fact -- but what we have suggested -- I can't prove  
17 this. But what we've suggested is what we're really seeing is there are  
18 places in the model where we have the least information about activity  
19 levels or the model's most vulnerable, if you will, to underestimating  
20 exposure.

21 There are ways that we can look at and can play with some

116

1 sensitivity analysis to know whether or not what you're suffering is a  
2 lack of data or whether or not you can compensation for it by things  
3 such as increasing the time of the day that you're spent on another  
4 field. That does not solve, however, the issue how much time as part  
5 of your life are the exposure opportunities changing.

6 As part of this whole thing, I think that the EPA certainly has  
7 done a wonderful job in incorporating a lot of these. And I'm very  
8 pleased to hear the comments from the Panel because you zeroed in on  
9 many of the issues.

10 My last comment about Beth's presentation, and I'll make a  
11 suggestion for how you can deal with some of the points she brought  
12 up. If you take an assessment of all of the -- what she showed you was  
13 a situation for a person. Let's say you have a thousand people across  
14 your simulated population. Each of those thousand people have a  
15 different scenario. Some will be naive with one peak; some will be  
16 naive with two, three, six peaks; some not be not native with no peaks.  
17 Same situation.

18 Well, you can't, I presume, regulate person by person in the  
19 United States. You're going to go and look at across population. And  
20 there are methods for doing that presently available.

21 What you can do is take and look at the peak values, the

117

1 maximum values, across all the people in the population. And then,  
2 also, take the averages, you can do that even one day at a time or  
3 across rolling windows whatever, and the difference between those  
4 two distributions gives you an indication of the frequency in which  
5 peaks happen.

6 If you have 90 days for example, if you have 80 of those days  
7 with peaks, the average of that scenario in the population is going to  
8 look a lot more like the peak, the maximum of the peaks. As these two  
9 things converge, what you have is a frequency of events within that  
10 time period. The farther apart they are, it insinuates that you have  
11 very rare events, rare peaks happening in the group.

12 Now, that just gives some guidance, I think, to the regulator as  
13 to whether or not you really should be looking at applications of acute  
14 metrics or applications that may be long-term exposure scenarios.  
15 You can do this across -- and we've done this frequently -- 1 day, 7  
16 day -- this is rolling window -- 30 days, 90 days, and 365 days; and  
17 then just compare just for the exposures. Be dammed the toxicology  
18 now.

19 Just for the exposure to see how similar these numbers are  
20 because that gives you an indication of whether you're looking at  
21 peaks across frequencies that are daily events, weekly events, monthly

118

1 events, seasonal situations, or annual situations. And the differences  
2 between these distributions at least opens up an idea as to whether  
3 you're dealing frequently occurring scenarios for exposure or not.

4 And I would recommend that that approach be taken at least to  
5 take a look at to give you some confidence that you're using the  
6 correct toxicology metrics. There are techniques such as this that are  
7 available, and I think they will be hopefully a point of discussion in the  
8 future.

9 So we'll put this down in writing very, very quickly and try to  
10 get it to you. Maybe it will be helpful. Thank you.

11 DR. ROBERTS: Thanks, Dr. Chasen. Could you give us an  
12 idea on the time frame for completion of your Lifeline analysis? You  
13 mentioned that you will have that available.

14 DR. CHASEN: Well, we're just going sort of going to go as fast  
15 as we can. But it certainly will be available between now and June.

16 DR. ROBERTS: All right. Thank you. Other questions? Dr.  
17 McConnell.

18 DR. MCCONNELL: Yeah, I have a question. I was intrigued  
19 by your last comment where you said you'd have some data for one  
20 day, seven. What sort of magnitude difference was there in those  
21 values for exposure if you look at a 365 day versus a 7 day? Were

119

1 they significantly different?

2 DR. CHASEN: Are you talking about for the OPs?

3 DR. MCCONNELL: Yeah.

4 DR. CHASEN: I haven't done it for the OPs yet.

5 DR. MCCONNELL: Well, whatever.

6 DR. CHASEN: I didn't get that far.

7 DR. MCCONNELL: Well, whatever chemical.

8 DR. CHASEN: Well, it depends on the use scenario and the  
9 chemical you're talking about.

10 In cases where you have a pattern that is seasonally or  
11 dependent upon seasonal activities, you're going to suddenly see a  
12 break in the 1 year and one day won't look like the 90 day. And maybe  
13 the 30 daily will look like the 1 day. And then all of a sudden there'll  
14 be a big difference between the distribution of the peak values between  
15 the distribution described by a 30-day rolling window versus a 90-day  
16 rolling window.

17 Now, there is no such thing as frequency data, per se. But this  
18 infers frequency. I get nervous with all these statisticians sitting, and  
19 I say things like that. It's only meant as a tool to give you an idea of  
20 whether or not you're looking at frequently occurring scenarios where  
21 you have a lot of people seeing frequent peaks or a few people seeing

120

1 frequent peaks or a lot of people seeing some kind of seasonal peaks  
2 or something like that.

3 So the models can give you more than just a risk assessment.  
4 What they can do is provide ways to play with profiling. Okay. And  
5 then from there maybe you go back and take a look at the toxicology  
6 metrics that may be most appropriate to deal with this. And you can  
7 look at that across populations or subpopulations.

8 And I will, also, point out to you that here's another dilemma.  
9 Those relationships change with age. That shouldn't be a surprise.  
10 Think about how the time you spend in your day, change your  
11 exposure opportunities, and if you're a 6-year-old, that's going to look  
12 very different than if you're 35 or if you're 56. And so those  
13 relationships -- I don't know what -- I mean I think this -- I don't want  
14 to confound this too much, but I do think it's important to look at  
15 these things at different time and groups to see, in fact, where are we  
16 seeing those kinds of shifts.

17 DR. MCCONNELL: Thank you.

18 DR. ROBERTS: Any other questions for Dr. Chasen? If not,  
19 thanks very much for your comments.

20 DR. CHASEN: Thank you.

21 DR. ROBERTS: Is there anyone else in the audience that would

121

1 like to address the Panel on this subject. Oh, I see someone in the  
2 back.

3 Welcome. Could you please identify yourself for the Panel.

4 MR. GRAY: Sure. My name is Ed Gray. I work at McDermott,  
5 Will & Emery. I'm really not here on behalf of anyone else, although I  
6 do a lot of work with the IWG.

7 I just wanted to raise one question that just occurred to me as  
8 this thing came up. And that is it seems like in almost every hazard or  
9 risk assessment that anyone does they have a series of different kinds  
10 of assessment they do. They do an acute. They do a subchronic. They  
11 do a chronic. And they do that because they recognize there are  
12 differences in the exposures as well as the toxicity endpoints. But  
13 here we seem to be trying to make different things into one thing. And  
14 I can't figure out why we can't just do two.

15 That's my question. I don't have any profound back up on that,  
16 but it seems to be a question that ought to be raised. Thanks.

17 DR. ROBERTS: Dr. McConnell wants to know what are the  
18 two?

19 DR. MCCONNELL: Yeah. Are you talking acute and chronic  
20 when you're say two?

21 MR. GREY: Yes.

1 DR. ROBERTS: Any other comments or responses to that from  
2 the Panel? All right. Anyone else in the audience? The last  
3 opportunity for public comment.

4 Dr. Sass, could you identify yourself for the record, please.

5 DR. SASS: Jennifer Sass with the National Resources Defense  
6 Council.

7 This is an idea not a comment. It appears to me that possibly  
8 one thing that might be on the table for consideration in looking at the  
9 rolling windows -- and I'm calling them in my notes the rolling window  
10 averages -- is that it might go to tackle some of the problems including  
11 possibly seasonality which I think we all recognize is a serious  
12 omission is to do a rolling window.

13 And I like Chris's idea of doing different time periods as a first  
14 trial, time permitting and energy permitting. But, also, keeping the  
15 having the diets the way they are which is two diets alternating  
16 throughout the year but keeping the tolerances constant for that  
17 rolling window period. So if you chose a seven-day rolling window  
18 period, you'd have the diet as is already -- sorry -- residues -- hold the  
19 residues constant for the period of seven days so that it would tackle  
20 the problem of the leftover food in the fridge; or the realistic scenario  
21 where people buy their groceries once a week or four days if you want

123

1 to do that kind of window; and then eat whatever's in that market  
2 basket so to speak in your refrigerator for those four days so that  
3 whatever the residues are in those grapes or those apples that's what  
4 you're getting for X number of days.

5 So holding those residues constant. It would also tackle in  
6 some way possibly the seasonality if you use that approach to try and  
7 get at the fact that you eat a lot of peaches for a long time when peach  
8 season is here and not so much at other times, and you might be able  
9 to extend that.

10 I think it might, also, tackle some of the Beth's diagrams, which  
11 I thought were excellent and really clear, in the sense that those peaks  
12 would be muted out; but they would, also, be extended and they might  
13 be more easier to detect. So that when we look over a period of a year  
14 and see what looks to me like something you might get off a radial,  
15 like this, then, actually, some of those larger peaks would be extended  
16 for a period of seven days rather than one which might be a more  
17 realistic -- well, I think it is a more realistic scenario at least in some  
18 eating patterns. And certainly I think we recognize in children who  
19 don't have a varied diet but a pretty constant diet often high in fruits.  
20 Fruits anyway; I don't know about vegetables. And so those peaks  
21 might be extended and more recognizable and in a way more realistic

124

1 and capture that.

2 DR. ROBERTS: Okay. Any responses or comments from the  
3 Panel? I think we have another public commentor. Dr. Schreiber.

4 DR. SCHREIBER: Dr. Schreiber, from the Attorney General's  
5 Office.

6 I didn't realize this was our last opportunity to comment today.  
7 So I just wanted to raise a couple of issues I didn't actually hear  
8 discussed, but I wanted to just be on the record of bring them up.  
9 And, again, we will be providing more formal comments.

10 I didn't hear any discussion of how endocrine disruption effects  
11 are included or addressed in the OP cumulative risk assessment other  
12 than I know, in some of the materials I've read, it will be taken up at  
13 some point. Can you give us an idea of when it will be taken up and  
14 how we will know about it before the final cumulative risk assessment  
15 is completed? That's one question.

16 Along the same lines, at what point is the FQPA Safety Factor  
17 considered in this assessment? I haven't heard anything about the  
18 FQPA features of this assessment.

19 And then, finally, and perhaps most importantly, what does EPA  
20 and the Science Advisory Panel consider an appropriate MOE for OPs  
21 for the cumulative risk assessment? I think that's the million-dollar

125

1 question here. We see these, you know, graphics that show that the  
2 cumulative risks, at least on a few of those slides that I can recall, are  
3 somewhere in the range to 10 to 100 for the cumulative chronic risks.  
4 That seems to be over EPA's goal of 100 as a minimum MOE and that's  
5 without even considering this FQPA Safety Factor and endocrine  
6 disruption risks.

7 So I guess my question is a combination of when will the  
8 endocrine disruption risks be considered, when with the FQPA Safety  
9 Factor be considered, and what is an appropriate margin of exposure in  
10 terms of cumulative risks and when will you let us know?

11 DR. ROBERTS: Okay. Thank you, Dr. Schreiber, for offering  
12 those questions.

13 I don't know if there's any Panel members want to do any follow  
14 up or not. If not, we'll certainly take those into consideration as we  
15 get into our discussion a little bit later on.

16 DR. SCHREIBER: Thank you.

17 DR. ROBERTS: As Dr. Schreiber pointed out, and I would like  
18 to point out, that this is the last opportunity for public comment  
19 before we move into our discussions. Actually, it is the final  
20 opportunity for public comment on this topic. So with that in mind,  
21 last call for public commentators. Okay. With that, then we'll close the

126

1 public comment session.

2 I'm reluctant to go ahead and tackle the first question because  
3 it's a meaty one. And I'm not sure. I think if we go into it we might  
4 go very late before we get to lunch. So let's take a lunch break now,  
5 let everybody ready to go, their thoughts lined up. Let's reconvene at  
6 1:30 fresh and ready to go.

7 [Lunch recess.]

8 -oo0oo-

1  
2  
3  
4  
5  
6  
7  
8  
9

CERTIFICATE OF STENOTYPE REPORTER

I, Jane F. Hoffman, Stenotype Reporter, do hereby certify that the foregoing proceedings were reported by me in stenotypy, transcribed under my direction and are a verbatim record of the proceedings had.

-----

JANE F. HOFFMAN

128

1     \*\*I-N-V-O-I-C-E\*\*\*\*   \*\*\*\*I-N-V-O-I-C-E\*\*\*\*

2     JANE F. HOFFMAN

3     849 S. Irving Street

4     Arlington, VA 22204

5     SS#305-52-5988

6     TODAY'S DATE: 2/22/02

7     DATE TAKEN: 2/7/02

8     CASE NAME: FIFRA SAP MEETING/PRELIMINARY CUMULATIVE RISK  
9     ASSESSMENT

10    **TOTAL: -- PAGES: 185**

11    LOCATION OF DEPO: Arlington, VA

12    DELIVERY: Regular -- conference rate

13